{
  "name": "Epilepsy",
  "slug": "epilepsy",
  "icon": "⚡",
  "color": "bg-purple-100 text-purple-800 border-purple-200",
  "toc": [
    {
      "level": 1,
      "text": "Maintenance Antiseizure Medications",
      "id": "maintenance-antiseizure-medications"
    },
    {
      "level": 2,
      "text": "Antiseizure Medication Doses & Formulations",
      "id": "asm-doses-formulations"
    },
    {
      "level": 2,
      "text": "Antiseizure Medication Side-Effects",
      "id": "asm-side-effects"
    },
    {
      "level": 2,
      "text": "Antiseizure drug indications",
      "id": "antiseizure-drug-indications"
    },
    {
      "level": 1,
      "text": "Status Epilepticus Pathway",
      "id": "status-epilepticus-pathway"
    },
    {
      "level": 2,
      "text": "STATUS EPILEPTICUS IN CHILDREN OLDER THAN 28 DAYS",
      "id": "status-epilepticus-in-children-older-than-28-days"
    },
    {
      "level": 1,
      "text": "Status Epilepticus Antiseizure Medications",
      "id": "status-epilepticus-antiseizure-medications"
    },
    {
      "level": 3,
      "text": "First-Line Agents",
      "id": "first-line-agents"
    },
    {
      "level": 3,
      "text": "Second-Line Agents",
      "id": "second-line-agents"
    },
    {
      "level": 3,
      "text": "Third-Line Agents",
      "id": "third-line-agents"
    },
    {
      "level": 2,
      "text": "General suggestions on how to wean continuous infusions",
      "id": "general-suggestions-on-how-to-wean-continuous-infusions"
    },
    {
      "level": 2,
      "text": "General suggestions on how to wean continuous infusions",
      "id": "general-suggestions-on-how-to-wean-continuous-infusions-2"
    },
    {
      "level": 2,
      "text": "Electroencephalogram (EEG)",
      "id": "electroencephalogram-eeg"
    },
    {
      "level": 2,
      "text": "Other considerations in Management",
      "id": "other-considerations-in-management"
    },
    {
      "level": 2,
      "text": "Supportive Care Goals",
      "id": "supportive-care-goals"
    },
    {
      "level": 2,
      "text": "Diagnostic work-up/management of underlying causes of status epilepticus",
      "id": "diagnostic-work-up-management-of-underlying-causes-of-status"
    },
    {
      "level": 1,
      "text": "Neonatal Seizures",
      "id": "neonatal-seizures"
    },
    {
      "level": 1,
      "text": "Neonatal Seizure Algorithm",
      "id": "neonatal-seizure-algorithm"
    },
    {
      "level": 2,
      "text": "IV Pyridoxine (vitamin B6) challenge",
      "id": "iv-pyridoxine-vitamin-b6-challenge"
    },
    {
      "level": 1,
      "text": "Home Seizure Rescue",
      "id": "home-seizure-rescue"
    },
    {
      "level": 2,
      "text": "Home Rescue for prolonged seizure:",
      "id": "home-rescue-for-prolonged-seizure"
    },
    {
      "level": 1,
      "text": "Bridging Sick Kids with Benzos",
      "id": "bridging-sick-kids-with-benzos"
    },
    {
      "level": 1,
      "text": "EEG Reading Basics",
      "id": "eeg-reading-basics"
    },
    {
      "level": 3,
      "text": "Helpful Tips:",
      "id": "helpful-tips"
    },
    {
      "level": 1,
      "text": "Ketogenic Diet",
      "id": "ketogenic-diet"
    },
    {
      "level": 1,
      "text": "Vagus Nerve Stimulator (VNS)",
      "id": "vagus-nerve-stimulator-vns"
    },
    {
      "level": 1,
      "text": "Infantile Spasms",
      "id": "infantile-spasms"
    },
    {
      "level": 2,
      "text": "Treatment choices:",
      "id": "treatment-choices"
    },
    {
      "level": 2,
      "text": "Follow-up for all therapies",
      "id": "follow-up-for-all-therapies"
    },
    {
      "level": 1,
      "text": "Febrile Seizures",
      "id": "febrile-seizures"
    },
    {
      "level": 2,
      "text": "Treatments:",
      "id": "treatments"
    },
    {
      "level": 3,
      "text": "PROGNOSIS",
      "id": "prognosis"
    },
    {
      "level": 1,
      "text": "First \"Unprovoked\" Afebrile Seizure",
      "id": "first-unprovoked-afebrile-seizure"
    },
    {
      "level": 1,
      "text": "Epilepsy Syndromes",
      "id": "epilepsy-syndromes"
    },
    {
      "level": 2,
      "text": "2017 Seizure Classification",
      "id": "2017-seizure-classification"
    },
    {
      "level": 3,
      "text": "Epilepsy diagnosis:",
      "id": "epilepsy-diagnosis"
    },
    {
      "level": 3,
      "text": "Syndromes:",
      "id": "syndromes"
    },
    {
      "level": 1,
      "text": "Epilepsy and Driving",
      "id": "epilepsy-and-driving"
    },
    {
      "level": 1,
      "text": "Seizure Semiology",
      "id": "seizure-semiology"
    },
    {
      "level": 1,
      "text": "Electroclincal Syndromes (by Age)",
      "id": "electroclincal-syndromes-by-age"
    },
    {
      "level": 1,
      "text": "Rite Review",
      "id": "rite-review"
    },
    {
      "level": 1,
      "text": "EEG Tips",
      "id": "eeg-tips"
    },
    {
      "level": 2,
      "text": "Alpha waves",
      "id": "alpha-waves"
    },
    {
      "level": 2,
      "text": "Beta waves",
      "id": "beta-waves"
    },
    {
      "level": 2,
      "text": "Theta waves",
      "id": "theta-waves"
    },
    {
      "level": 2,
      "text": "Delta waves",
      "id": "delta-waves"
    },
    {
      "level": 1,
      "text": "Valproic Acid (VPA) Toxicity",
      "id": "valproic-acid-toxicity"
    },
    {
      "level": 2,
      "text": "VPA-Induced Hyperammonemic Encephalopathy",
      "id": "vpa-hyperammonemic-encephalopathy"
    },
    {
      "level": 3,
      "text": "Recognition",
      "id": "vpa-toxicity-recognition"
    },
    {
      "level": 3,
      "text": "L-Carnitine Treatment Protocol",
      "id": "l-carnitine-protocol"
    },
    {
      "level": 3,
      "text": "VPA Overdose",
      "id": "vpa-overdose-management"
    }
  ],
  "html": "<h1 id=\"maintenance-antiseizure-medications\">Maintenance Antiseizure Medications</h1><h2 id=\"asm-doses-formulations\">Antiseizure Medication Doses &amp; Formulations for Long-Term Management</h2><div class=\"table-wrap\"><table><thead><tr><th><p><strong>Medication</strong></p><p><strong>Level ug/ml</strong></p></th><th><p><strong>Titration</strong></p></th><th><p><strong>Ped Dosing</strong></p></th><th><p><strong>Adult dose</strong></p></th><th><p><strong>Formulations</strong></p></th></tr></thead><colgroup><col style=\"width:15%\"><col style=\"width:25%\"><col style=\"width:25%\"><col style=\"width:20%\"><col style=\"width:15%\"></colgroup><tbody><tr><td><p><strong>Brivaracetam (Briviact)</strong></p><p>(C-V)</p></td><td></td><td><p>&lt;11 kg: 1.5-3 mg/kg/day divided BID; max: 6 mg/kg/day</p><p>11 to &lt;20 kg: Initial: 1-2.5 mg/kg/day div BID; max: 5 mg/kg/day</p><p>20 kg to &lt;50 kg: Initial: 1-2 mg/kg/day div BID; max: 4 mg/kg/day</p><p>≥50 kg: see adult dose</p></td><td><p>50 mg BID</p><p>*Increase to 100 mg BID or decrease to 25 mg BID depending on response and tolerance</p></td><td><p>Tab: 10, 25, 50, 75, 100 mg</p><p>Suspension 10 mg/mL</p><p>IV formulation available</p></td></tr><tr><td><p><strong>Cannabidiol (Epidiolex)</strong></p><p>(C-V)</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>1-5 mg/kg/day div BID</p><p><br>2.5-5 mg/kg/day q2-7 days</p><p>2.5 – 12.5 mg/kg/day div BID (max: 20 mg/kg/day)</p></td><td><p>5 mg/kg/day div BID</p><p>5 mg/kg/day div BID q2-7 days</p><p>5-20 mg/kg/day div BID (max: 20 mg/kg/day)</p></td><td><p>Sol: 100 mg/mL (100 mL)</p></td></tr><tr><td><p><strong>Carbamazepine (Tegretol)</strong></p><p> 4-12</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>5-10 mg/kg/day div BID</p><p>5-10 mg/kg/day weekly</p><p>15-45 mg/kg/day div q6-12h</p><p>Note: Has potential for auto-induction. Young children can be rapid metabolizers and may need to go by levels to adjust dose.</p></td><td><p>200 mg BID</p><p>200 mg/day weekly</p><p>800-1200 mg TID or BID if ER</p></td><td><p>Suspension: 100mg/5mL; can give rectally</p><p>Tab: 200 mg</p><p>Chew tab: 100 mg</p><p>ER tabs: 100, 200, 400 mg</p></td></tr><tr><td><p><strong>Clobazam (ONFI)</strong></p><p>(C-IV)</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>0.25 mg/kg/day div BID</p><p>0.25 mg/kg/day weekly</p><p>1-2 mg/kg/day (max: 80 mg/day; typ max 40mg/day)</p></td><td><p>5 mg BID</p><p>5-10 mg weekly</p><p>10-20 mg/day divided BID (max: 40 mg/day)</p></td><td><p>Suspension: 2.5 mg/mL</p><p>Tab: 5, 10, 20 mg</p><p>Film: 5, 10, 20 mg (Sympazan)</p></td></tr><tr><td><p><strong>Ethosuximide (Zarontin)</strong></p><p>40-100</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>10 mg/kg/day div BID</p><p>15 mg/kg/day weekly</p><p>45-60 mg/kg/day div BID/TID</p><p>Note: consider checking level to adjust.</p></td><td><p>250 mg BID</p><p>250 mg weekly</p><p>1000-2000 mg div BID/TID</p></td><td><p>Cap: 250 mg</p><p>Syrup: 250 mg/5ml</p></td></tr><tr><td><p><strong>Felbamate (Felbatol)</strong></p><p>50-150</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>15 mg/kg/day div TID</p><p>15 mg/kg/day weekly</p><p>45-60 mg/kg/day div TID-QID</p></td><td><p>400 mg TID</p><p>1200 mg weekly</p><p>1200 mg TID</p></td><td><p>Tabs: 400, 600 mg</p><p>Syrup: 120 mg/mL</p></td></tr><tr><td><p><strong>Gabapentin (Neurontin)</strong></p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>10-15 mg/kg/day div TID</p><p>10 mg/kg/day weekly</p><p>25-40 mg/kg/day div TID-QID (max 50 mg/kg/day)</p></td><td><p>300 mg TID</p><p>300 mg weekly</p><p>900-3600 mg/day div TID</p></td><td><p>Caps: 100, 300, 400 mg</p><p>Tabs: 600, 800 mg</p><p>Sol: 250mg/5ml</p></td></tr><tr><td><p><strong>Lacosamide (Vimpat)</strong></p><p>(C-V)</p><p>3-12</p></td><td></td><td><p><strong>&lt;6 kg</strong></p><p><strong>IV</strong><br><strong>Initial: 2 mg/kg/day div TID</strong><br><strong>Increase by: 2 mg/kd/day div TID q1 week</strong><br><strong>Maintenance: 7.5 to 15 mg/kg/day div TID</strong></p><p><strong>Oral</strong><br><strong>Initial: 2 mg/kg/day div BID</strong><br><strong>Increase by: 2 mg/kg/day div BID</strong><br><strong>Maintenance: 7.5 – 15 mg/kg/DAY div BID</strong></p><p><strong>6 to &lt;30 kg:</strong></p><p>Initial (both oral, IV): 2 mg/kg/day divided BID<br>Increase by: 2 mg/kg/day div BID q1 week<br>Maintenance: 6 – 12 mg/kg/day div BID</p><p><strong>30 to &lt;50 kg:</strong></p><p>Initial (both oral, IV): 2 mg/kg/day div BID<br>Increase by: 2 mg/kg/day div BID q1 week<br>Maintenance: 4 – 8 mg/kg/day div BID</p><p><strong>≥50 kg:</strong></p><p>Initial (both monotherapy and adjunctive therapy; both oral, IV): 50 mg twice daily<br>Increase by: 100 mg daily q1 week<br>Maintenance:<br>- Monotherapy: Oral, IV: 150 to 200 mg twice daily.<br>- Adjunctive therapy: Oral, IV: 100 to 200 mg twice daily.</p></td><td><p>50 mg BID</p><p>100 mg weekly</p><p>200 mg BID</p></td><td><p>Tab 50, 100, 150, 200 mg</p><p>Sol 10 mg/ml</p><p>IV available</p></td></tr><tr><td><p><strong>Lamotrigine (Lamictal)</strong></p><p>4-20 total/1-9 free</p><hr style=\"border:none;border-top:2px solid #7c3aed;margin:8px 0;\"><p><strong>WITH INDUCERS (carbamazepine, phenytoin, phenobarbital, primidone) and WITHOUT VPA</strong></p><hr style=\"border:none;border-top:2px solid #8b5cf6;margin:8px 0;\"><p><strong>WITH INDUCERS (carbamazepine, phenytoin, phenobarbital, primidone) and WITH VPA</strong></p><hr style=\"border:none;border-top:2px solid #a78bfa;margin:8px 0;\"><p><strong>WITH VPA and WITHOUT INDUCERS</strong></p><hr style=\"border:none;border-top:2px solid #c4b5fd;margin:8px 0;\"><p><strong>MONOTHERAPY or with antiseizure drugs other than carbamazepine, phenytoin, phenobarbital, primidone, or VPA</strong></p><hr style=\"border:none;border-top:1px dashed #94a3b8;margin:8px 0;\"><p><strong>NOTE: Lamotrigine dosing recommendations vary widely, consider discussing with an attending.</strong></p></td><td><br><br><br><hr style=\"border:none;border-top:2px solid #7c3aed;margin:8px 0;\"><br><p>Week 1-2</p><p>Week 3-4</p><p>Then increase</p><p>Typical maintenance</p><br><hr style=\"border:none;border-top:2px solid #8b5cf6;margin:8px 0;\"><br><p>Week 1-2</p><p>Week 3-4</p><p>Then increase</p><p>Typical maintenance</p><br><hr style=\"border:none;border-top:2px solid #a78bfa;margin:8px 0;\"><br><p>Week 1-2</p><p>Week 3-4</p><p>Then increase</p><p>Typical maintenance</p><br><hr style=\"border:none;border-top:2px solid #c4b5fd;margin:8px 0;\"><br><p>Week 1-2</p><p>Week 3-4</p><p>Then increase</p><p>Typical maintenance</p><br></td><td><br><br><br><hr style=\"border:none;border-top:2px solid #7c3aed;margin:8px 0;\"><p><strong>2yo-less than 16yo</strong></p><p>0.6-2 mg/kg/DAY div BID</p><p>1.2-5 mg/kg/DAY div BID</p><p>1.2-5 mg/kg/DAY div BID q2wks</p><p>5-15 mg/kg/DAY div BID or TID (max 400 mg/DAY)</p><hr style=\"border:none;border-top:2px solid #8b5cf6;margin:8px 0;\"><p><strong>2yo-less than 16yo</strong></p><p>0.2 mg/kg/DAY daily or div BID</p><p>0.5 mg/kg/DAY div BID</p><p>1 mg/kg/DAY q1-2 wks</p><p>5 mg/kg/DAY div BID (max 250 mg/DAY)</p><hr style=\"border:none;border-top:2px solid #a78bfa;margin:8px 0;\"><p><strong>2yo-less than 16yo</strong></p><p>0.1-0.2 mg/kg/DAY daily</p><p>0.2-0.5 mg/kg/DAY daily</p><p>0.3-1 mg/kg/DAY q1-2 wks</p><p>1-3 mg/kg/DAY daily or div BID (max 150-200 mg/DAY)</p><hr style=\"border:none;border-top:2px solid #c4b5fd;margin:8px 0;\"><p><strong>2yo-less than 16yo</strong></p><p>0.3 mg/kg/DAY daily or div BID</p><p>0.6 mg/kg/DAY div BID</p><p>0.6 mg/kg/DAY q1-2 wks</p><p>4.5-7.5mg/kg/DAY div BID (max 300 mg/DAY)</p><p>Note: can use levels to adjust further</p></td><td><br><br><br><hr style=\"border:none;border-top:2px solid #7c3aed;margin:8px 0;\"><p><strong>16yo and older</strong></p><p>50 mg q24h</p><p>50 mg q12h</p><p>100 mg/DAY q2wks</p><p>300-500 mg/DAY div BID or 400-600 mg daily [ER]</p><hr style=\"border:none;border-top:2px solid #8b5cf6;margin:8px 0;\"><p><strong>16yo and older</strong></p><p>25 mg q48h</p><p>25 mg q24h</p><p>25-50 mg/DAY q1-2 wks (can div BID)</p><p>100-150 mg/DAY div BID</p><hr style=\"border:none;border-top:2px solid #a78bfa;margin:8px 0;\"><p><strong>16yo and older</strong></p><p>12.5-25 mg q48h</p><p>25 mg daily</p><p>25-50 mg/DAY q1-2wks</p><p>100-200 mg div BID or in 200-250mg daily [ER]</p><hr style=\"border:none;border-top:2px solid #c4b5fd;margin:8px 0;\"><p><strong>16yo and older</strong></p><p>25 mg q24h</p><p>50 mg q24h or div BID</p><p>50 mg/DAY q1-2wks</p><p>225-375 mg/DAY div BID or 300-400 mg daily [ER]</p></td><td><br><br><br><p>Tablets 25, 100, 150, 200 mg</p><p>Chew tablets 2, 5, 25 mg</p><p>ODT 25, 20, 100, 200 mg</p><p>XR 25, 50, 100, 200, 300 mg</p><p>*round dose down to the nearest whole tablet</p></td></tr><tr><td><p><strong>Levetiracetam (Keppra)</strong></p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>10 mg/kg/day div BID</p><p>10-20 mg/kg/day weekly</p><p>40-60 mg/kg/day div BID</p></td><td><p>500 mg BID</p><p>500-1000 mg wkly</p><p>1500 mg BID  </p></td><td><p>Tab: 250, 500, 750, 1000 mg</p><p>Sol: 100 mg/ml</p><p>XR tabs: 500, 750</p><p>IV available</p></td></tr><tr><td><p><strong>Methsuximide (Celontin)</strong></p><p>25-45 mcg/mL for NDMSM</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>5 mg/kg/day daily</p><p>3.2-5.5 mg/kg/day weekly</p><p>Max 30 mg/kg/day (or 1200 mg/DAY div BID)</p></td><td><p>300 mg daily</p><p>300 mg/DAY weekly</p><p>1200 mg/DAY div BID</p></td><td><p>Caps: 150, 300 mg</p></td></tr><tr><td><p><strong>Oxcarbazepine (Trileptal)</strong></p><p>15-50</p><p>(consider TID &lt;5yrs)</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>8-10 mg/kg/day div BID</p><p>5-10 mg/kg/day weekly</p><p>20-45 mg/kg/day div BID (max 60 mg/kg/day)</p></td><td><p>300 mg BID</p><p>600 mg/day wkly</p><p>1200 mg BID</p></td><td><p>Tabs: 150, 300, 600 mg</p><p>Susp: 300mg/5ml</p><p>XR: 150, 300, 600 mg</p></td></tr><tr><td><p><strong>Perampanel (Fycompa)</strong></p><p> (C-III)</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>2 mg qHS (if no CYP3A4 inducer); 4mg qHS with inducer</p><p>2 mg weekly</p><p>8 -12 mg QHS (max: 12mg/day)</p></td><td><p>2 mg QHS (if no CYP3A4 inducer)</p><p>2 mg weekly</p><p> 8 -12 mg QHS</p></td><td><p>Susp: 0.5 mg/mL (340 mL)</p><p>Tab: 2,4,6,8,10,12 mg</p></td></tr><tr><td><p><strong>Phenobarbital (Luminal)</strong></p><p>(C-IV)</p><p>15-40</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>2-6 mg/kg/day daily or div BID</p><p>1-2 mg/kg/day q2 weeks</p><p>2-6 mg/kg/day div BID</p></td><td><p>60-90 mg QHS</p><p>30 mg/day monthly</p><p>60-120 mg/day div QD/BID</p></td><td><p>Elixir 20 mg/5ml (contains 15% alcohol)</p><p>Tab 15, 16.2, 30, 32.4, 60, 64.8, 97.2, 100 mg</p><p>IV available, 1:1 conversion</p></td></tr><tr><td><p><strong>Phenytoin (Dilantin)/ Fosphenytoin (Cerebryx)</strong></p><p>10-25</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>4-7 mg/kg/day div BID-TID</p><p>1-2 mg/kg/day q2 weeks</p><p>4-8 mg/kg/day div BID-TID</p></td><td><p>300 mg div QD/BID</p><p>200-600 mg QD/BID</p></td><td><p>Injection: 50 mg/ml</p><p>Susp: 25 mg/ml (shake well)</p><p>Chew tab: 50 mg</p><p>Caps 30, 100, 200, 300 mg</p><p>IV available; conversion varies</p></td></tr><tr><td><p><strong>Pregabalin (Lyrica)</strong></p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>1-2 mg/kg/day div TID x 4 days</p><p>1-2 mg/kg/day q3-4 days</p><p>5-20 mg/kg/day div q6-8h</p></td><td><p>50 mg TID</p><p>150 mg/day weekly</p><p>150-600 mg/day div BID/TID</p></td><td><p>Tab 25, 50, 75, 100, 150, 200, 225, 300 mg</p><p>Susp: 20 mg/mL</p></td></tr><tr><td><p><strong>Primidone (Mysoline)</strong></p><p>4-12 PHB; 15-40</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>1-2 mg/kg/day x 4 days</p><p>1-2 mg/kg/day q3-4 days</p><p>5-20 mg/kg/day div TID/QID</p></td><td><p>62.5 mg QHS</p><p>62.5 mg q3-4 days</p><p>10-20 mg/kg/day div TID</p></td><td><p>Tab: 50, 250 mg</p><p>Susp: 250 mg/5 mL</p></td></tr><tr><td><p><strong>Rufinamide (Banzel)</strong></p><p>5-55</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>10 mg/kg/day div BID</p><p>5-10 mg/kg/day weekly</p><p>45 mg/kg/day div BID</p></td><td><p>400-800 mg BID</p><p>400-800 mg QOD</p><p>3200 mg/day div BID</p></td><td><p>Tab 200, 400 mg</p><p>Susp: 40 mg/mL (460 mL)</p></td></tr><tr><td><p><strong>Stiripentol (Diacomit)</strong></p></td><td></td><td><p>Given w/Onfi +Valproate</p><p>See epileptologist</p></td><td><p>10 -15 mg/kg/day</p><p>50 mg/kg/day div BID/TID</p></td><td><p>Caps 250, 500 mg</p><p>Powder: 250 mg 500 mg (60 ea)</p></td></tr><tr><td><p><strong>Topiramate (Topamax; also Qudexy XR cap, Trokendi XR cap, and Eprontia solution)</strong></p><p>5-25</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>0.5-1mg/kg/day div daily or BID</p><p>0.5-1 mg/kg/day q1-2 week</p><p>5-9 mg/kg/day div BID (150-400 mg/day)</p></td><td><p>25-50 mg daily or div BID</p><p>25-50 mg/day q1 week</p><p>200-400 mg div BID</p></td><td><p>Tab: 25, 50, 100, 200 mg</p><p>Sprinkles: 15, 25 mg</p><p>Sol: Compounded liquid 6 mg/mL (req. comp pharm); Eprontia solution 25 mg/mL (120, 240, or 473 mL/bottle)</p></td></tr><tr><td><p><strong>Valproate sodium (Depakene solution, Depacon IV)</strong></p><p><strong>Valproic acid (Depakene cap)</strong></p><p><strong>Divalproex sodium (Depakote tab/Depakote sprinkle caps/Depakote ER tab)</strong></p><p>These are NOT all equivalent. Use caution when prescribing. Discuss any conversions with pharmacy. </p><p>50-100</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>10-15 mg/kg/day div BID</p><p>10-15 mg/kg/day weekly</p><p>30-60 mg/kg/day div BID-TID</p><p>Note: consider checking level to adjust.</p></td><td><p>250-500 mg BID</p><p>250 mg/day weekly</p><p>1000-3000 mg/day div BID-TID</p></td><td><p>Solution (Depakene) 50 mg/ml (dosed TID, can give rectally)</p><p>Caps (Depakene): 250 mg TID</p><p>Sprinkle (Depakote): 125 mg BID</p><p>DR tab (Depakote): 125, 250, 500 mg BID</p><p>ER tab (Depakote ER): 250, 500 mg daily or BID</p><p>IV available (Depacon; typically q6)</p></td></tr><tr><td><p><strong>Vigabatrin (Vigadrone, Sabril)</strong></p><p>*Supplied from specialty pharmacies</p><p>* Requires REMS program patient enrollment and REMS authorized prescriber, including when prescribing inpatient.  See below under “Infantile Spasms.”</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>15-50 mg/kg/DAY div BID</p><p>15-50 mg/kg/DAY weekly</p><p>50-150 mg/kg/DAY div BID</p></td><td><p>500 mg BID</p><p>500 mg/DAY weekly</p><p>1500 mg BID</p></td><td><p>Tab: 500 mg</p><p>PO powder sachet: 500mg (dilute with 10mL water for 50mg/mL)</p></td></tr><tr><td><p><strong>Zonisamide (Zonegran; also Zonisade solution)</strong></p><p> 10-40</p></td><td><p>Starting dose</p><p>Increase by</p><p>Typical maintenance</p></td><td><p>1-2 mg/kg/day div daily/BID</p><p>1-2 mg/kg/day q1-2 wk</p><p>4-8 mg/kg/day div BID (max 12 mg/kg/day or maximum daily dose of 500 mg/day)</p></td><td><p>100-200 mg/day QD/BID</p><p>100 mg wkly</p><p>200-600 mg/day QD/BID</p></td><td><p>Caps: 25, 50, 100 mg</p><p>Liquid: Compounded liquid 10 mg/mL; Zonisade solution 100 mg/5 mL (150 mL)</p></td></tr></tbody></table></div>\n<h2 id=\"asm-side-effects\">Antiseizure Medication Side-Effects (Always Relay Black Boxed Warnings)</h2><div class=\"table-wrap\"><table><thead><tr><th><p><strong>Medication</strong></p><p><strong>FDA approved</strong></p></th><th><p><strong>Idiosyncratic</strong></p></th><th><p><strong>Dose related</strong></p></th><th><p><strong>Age Specific/other</strong></p></th></tr></thead><tbody><tr><td><p><strong>Brivaracetam/Briviact</strong></p><p><strong>2016</strong></p></td><td><p>Psychiatric, ataxia, dizziness, </p></td><td><p>Drowsiness, fatigue</p></td><td></td></tr><tr><td><p><strong>Cannabidiol (Epidiolex)</strong></p><p><strong>2018</strong></p></td><td><p>Anemia, infection, GI upset</p></td><td><p>Sedation, diarrhea, liver toxicity</p></td><td><p>Medication interactions (e.g., Clobazam)</p></td></tr><tr><td><p><strong>Carbamazepine/ Tegretol/XR </strong></p><p><strong>1968</strong></p></td><td><p>Dermatologic (SJS) rare hematologic, hepatic, SIADH, fluid retention</p></td><td><p>Vertigo, visual disturbance (diplopia), lethargy, leukopenia</p></td><td><p>Low Na in adults; myoclonus in pts with general S/W, osteopenia</p></td></tr><tr><td><p><strong>Clobazam/Onfi</strong></p><p><strong>2011</strong></p></td><td><p>Urticarial type reaction, SJS, rare. </p></td><td><p>Sedation, ataxia, inc appetite, irritability</p></td><td></td></tr><tr><td><p><strong>Ethosuximide/Zarontin </strong></p><p><strong>2000</strong></p></td><td><p>Leukopenia, nephrotic syn, SLE, SJS, HA liver</p></td><td><p>Sedation, GI upset, hiccups</p></td><td><p>Behavioral</p></td></tr><tr><td><p><strong>Ezogabine/Potiga</strong></p><p><strong>2011</strong></p></td><td><p>Bluish discoloration, retinal damage</p></td><td><p>Urinary retention, Sedation, ataxia</p></td><td><p>Vision loss</p></td></tr><tr><td><p><strong>Felbamate/ Felbatol</strong></p><p><strong>2011</strong></p></td><td><p>Aplastic Anemia (adults only?), liver, rash</p></td><td><p>Anorexia, insomnia, HA, V, irritability</p></td><td><p>Aplastic anemia (post pubertal/); drug interactions</p></td></tr><tr><td><p><strong>Fycompa/Perampanel</strong></p><p><strong>2015</strong></p></td><td><p>Mood, DRESS</p></td><td><p>Dizzy, vertigo, aggression</p></td><td><p>Serious psych, behavioral s/e, interacts w/CYP3A4 inducers</p></td></tr><tr><td><p><strong>Gabapentin/ Neurontin</strong></p><p><strong>1993</strong></p></td><td><p>Rash (rare)</p></td><td><p>wt gain, vision, edema, GERD, hiccups, irritability, dizziness</p></td><td><p>Renal excretion, no drug interactions</p></td></tr><tr><td><p><strong>Lacosamide/Vimpat</strong></p><p><strong>2008</strong></p></td><td><p>Rash</p></td><td><p>Dizziness, ataxia, AV block</p></td><td><p>Syncope (adults)</p></td></tr><tr><td><p><strong>Lamotrigine/Lamictal</strong></p><p><strong>1994</strong></p></td><td><p>Rash, hypersensitivity reaction, abdominal pain, alopecia, SJS</p></td><td><p>Ataxia, diplopia, GI, HA, fatigue, N/V drowsiness, nystagmus</p></td><td><p>Rash (probably 5%, esp in kids), SJS</p></td></tr><tr><td><p><strong>Levetiracetam/ Keppra </strong></p><p><strong>1999</strong></p></td><td><p>none reported to date</p></td><td><p>Ataxia, dizzy, low blood cts, nervous, behavioral</p></td><td><p>Agitation, aggression, depression (5-10%?)</p></td></tr><tr><td><p><strong>Methsuximide/Celontin</strong></p><p><strong>1982</strong></p></td><td><p>Aggressiveness, auditory hallucinations</p></td><td><p>Ataxia, GI upset</p></td><td></td></tr><tr><td><p><strong>Oxcarbazepine/Trileptal/XR</strong></p><p><strong>2000 </strong></p></td><td><p>Rash (25% cross-reactivity with CBZ), SJS</p></td><td><p>dizziness, diplopia, headache,</p></td><td><p>Hyponatremia (3% of adults) behavior, Wt gain</p></td></tr><tr><td><p><strong>Phenobarbital/ Luminal </strong></p></td><td><p>Rash, SJS, SLE, hyperactivity</p></td><td><p>Irritability, wt gain, cognitive impairment, ataxia, respiratory dep</p></td><td><p>Possible irreversible cognitive effects, liver induc. inc bone metabolism</p></td></tr><tr><td><p><strong>Phenytoin/ Dilantin/    Cerebryx (Fosphenytoin)</strong></p><p><strong>2002</strong></p></td><td><p>rash (5-10%), blood, liver, LAD, folate def</p></td><td><p>Cosmetic, ataxia nystag. (propylene glycol in IV causes heart effects, dec HR, low BP)</p></td><td><p>Elevated LFTs, induction, reduced vit D, cerebellar degeneration? Increased bone metabolism</p></td></tr><tr><td><p><strong>Potassium Bromide (available in Germany)</strong></p></td><td><p>Psychosis, delirium</p></td><td><p>Depression, lethargy, somnolence, cerebral edema</p></td><td></td></tr><tr><td><p><strong>Pregabalin/Lyrica</strong></p><p><strong>2004</strong></p></td><td><p>Rash rare</p></td><td><p>Edema, dizzy, sedation, ataxia, HA, wt gain</p></td><td></td></tr><tr><td><p><strong>Primidone/ Mysoline </strong></p><p><strong>1954</strong></p></td><td><p>Rash</p></td><td><p>Sedation, irritability, GI upset</p></td><td><p>Similar to PB</p></td></tr><tr><td><p><strong>Rufinamide/ Banzel</strong></p><p><strong>2008</strong></p></td><td><p>QT shortening, rash, HA </p></td><td><p>Mood/psych, sedation, cerebellar, GI, HA</p></td><td></td></tr><tr><td><p><strong>Stiripentol/Diacomit</strong></p><p><strong>2018</strong></p></td><td><p>SJS, ataxia, weight changes (gain or loss), vomiting, sialorrhea </p><p>Neutropenia </p><p>Tremor </p></td><td><p>Drowsy/hypotonia, hyperexcitability/agitation, irritability</p></td><td></td></tr><tr><td><p><strong>Sulthiame/Ospolot</strong></p></td><td><p>Ataxia, paresthesia, SJS, leukopenia</p></td><td><p>Vomiting, hypotension, metabolic acidosis</p></td><td></td></tr><tr><td><p><strong>Tiagabine/Gabitril </strong></p><p><strong>1997</strong></p></td><td><p>Psychiatric </p></td><td><p>Tremor, HA, GI, gait, dizziness, attention to</p></td><td></td></tr><tr><td><p><strong>Topiramate/Topamax </strong></p><p><strong>2004</strong></p></td><td><p>Rash, acute glaucoma, hyperCl met acid, renal stones, hyperthermia, </p></td><td><p>Language and attention difficulties, anorexia, fatigue, paresthesia</p></td><td><p> Avoid keto diet; oligohydrosis</p></td></tr><tr><td><p><strong>Valproic Acid/ Depakene/ Depakote/ ER </strong></p><p><strong>2008</strong></p></td><td><p>Hepatic Failure; pancreatitis</p></td><td><p>Tremor, wt gain, alopecia, plt dysfxn, dec plt, menstrual cycle</p></td><td><p>Hepatic failure (1/500 under age 2 on polypharm) GI upset with syrup; PCOS</p></td></tr><tr><td><p><strong>Vigabatrin Max/ Sabril </strong></p><p><strong>2009</strong></p></td><td><p>Visual field loss, sedation, CNS</p></td><td><p>Psychiatric sxs (rare), ataxia, wt gain, blood dyscrasia</p></td><td><p>MRI white matter changes&nbsp;</p></td></tr><tr><td><p><strong>Zonisamide/ Zonegran </strong></p><p><strong>2000</strong></p></td><td><p>rash, hematologic, hepatic</p></td><td><p>renal stones, fatigue, wt loss psychosis, ataxia, parasthesias, diplopia</p></td><td><p>Oligohydrosis in children; cross sensitivity with sulfa </p></td></tr></tbody></table></div><img src=\"/images/epilepsy/img-2.jpg\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-35.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-34.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-33.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p>Drug rash: DPH (diphenylhydantoin), carbamazepine/oxcarbazepine, lamotrigine, zonisamide, felbamate              </p><p>Sulfa moiety: Topiramate, zonisamide, acetazolamide</p><p>Meds to adjust with renal failure: Gabapentin, levetiracetam, zonisamide, topiramate</p><p><strong>Also consider:  Anakinra (for FIRES), steroids, cenobamate (Xcopri), potassium bromide, piracetam (available in Mexico), sulthiame/sultiame (Ospolot; available in Europe)</strong></p><h2 id=\"antiseizure-drug-indications\">Antiseizure Drug Indications</h2><img src=\"/images/epilepsy/img-1.jpg\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p><em>Source: CONTINUUM: Lifelong Learning in Neurology. 22(1, Epilepsy):132-156, February 2016.</em></p><img src=\"/images/epilepsy/img-3.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><div class=\"table-wrap\"><table><thead><tr><th>Antiepileptic Drug</th><th>Focal Seizures</th><th>Generalized Tonic-Clonic Seizures</th><th>Generalized Absence Seizures</th><th>Generalized Myoclonic Seizures</th><th>Lennox-Gastaut Syndrome (LGS) or Infantile Spasms (IS)</th></tr></thead><tbody><tr><td><strong>Phenobarbital</strong></td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Not effective</td><td>Class IV evidence</td><td></td></tr><tr><td><strong>Phenytoin</strong></td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Carbamazepine</strong></td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Oxcarbazepine</strong></td><td>Class I trials</td><td>Unknown</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Eslicarbazepine acetate</strong></td><td>Class I trials</td><td>Unknown</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Valproate</strong></td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Suggested, but not proven in Class I trials</td></tr><tr><td><strong>Ethosuximide</strong></td><td>Not effective</td><td>Not effective</td><td>Class I trials</td><td>Not effective</td><td></td></tr><tr><td><strong>Clobazam</strong></td><td>Suggested, but not proven in Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Class I trials LGS</td></tr><tr><td><strong>Felbamate</strong></td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Unknown</td><td>Unknown</td><td>Class I trials LGS</td></tr><tr><td><strong>Gabapentin</strong></td><td>Class I trials</td><td>Not effective</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Pregabalin</strong></td><td>Class I trials</td><td>Not effective</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Lamotrigine</strong></td><td>Class I trials</td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Variable</td><td>Class I trials LGS</td></tr><tr><td><strong>Topiramate</strong></td><td>Class I trials</td><td>Class I trials</td><td>Not effective in one Class I trial</td><td>Unknown</td><td>Class I trials LGS</td></tr><tr><td><strong>Tiagabine</strong></td><td>Class I trials</td><td>Not effective</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Levetiracetam</strong></td><td>Class I trials</td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Class I trials</td><td></td></tr><tr><td><strong>Zonisamide</strong></td><td>Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Suggested, but not proven in Class I trials</td><td>Suggested, but not proven in Class I trials</td><td></td></tr><tr><td><strong>Lacosamide</strong></td><td>Class I trials</td><td>Unknown</td><td>Not effective</td><td>Not effective</td><td></td></tr><tr><td><strong>Vigabatrin</strong></td><td>Class I trials</td><td>Not effective</td><td>Not effective</td><td>Not effective</td><td>Class I trials IS</td></tr><tr><td><strong>Rufinamide</strong></td><td>Class I trials, but not FDA approved</td><td>Suggested, but not proven in Class I trials</td><td>Unknown</td><td>Unknown</td><td>Class I trials LGS</td></tr></tbody></table></div><img src=\"/images/epilepsy/img-17.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><h1 id=\"status-epilepticus-pathway\">Status Epilepticus Pathway</h1><p>A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus” 2015:</p><img src=\"/images/epilepsy/img-4.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><h2 id=\"status-epilepticus-in-children-older-than-28-days\"><strong>STATUS EPILEPTICUS IN CHILDREN OLDER THAN 28 DAYS</strong></h2><img src=\"/images/epilepsy/img-7.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-8.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-6.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-5.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><h1 id=\"status-epilepticus-antiseizure-medications\">Status Epilepticus Antiseizure Medications</h1><h3 id=\"first-line-agents\"><strong>First-Line Agents</strong></h3><ul><li>·       <strong>Benzodiazepines are most effective when administered within the first 5-10 minutes of seizure activity, before GABA receptors have internalized.  Choose ONE of the following options:</strong></li><li>·       <strong>Lorazepam IV:</strong> 0.1 mg/kg (max 4 mg) administered over 2 minutes.  A second dose can be administered if the seizure persists beyond 3-5 mins after the first dose.</li><li>·       <strong>Diazepam IV:</strong> 0.15-0.2 mg/kg (max 10 mg) administered over 2 minutes.  A second dose can be administered if the seizure persists beyond 3-5 mins after the first dose.</li><li>·       <strong>If IV access is not available, choose ONE of the following options:</strong><ul><li>  Midazolam intramuscular: <ul><li> For patients weighing 13-40 kg, give 5 mg</li><li> for patients &gt;40 kg, give 10 mg</li></ul></li><li> Midazolam intranasal: <ul><li> 0.2 mg/kg total (max 10 mg total), give 0.1 mg/kg into EACH nostril</li></ul></li><li> Diazepam rectal gel:<ul><li> 6-12 months old and weight 5-9.9 kg, give 2.5 mg.</li><li> 6-12 months old and weight at least 10 kg, give 5 mg. </li><li> 1-5 years old, give 0.5 mg/kg</li><li> 6-11 years old, give 0.3 mg/kg</li><li> 12+ years old, give 0.2 mg/kg. </li></ul></li></ul></li></ul><h3 id=\"second-line-agents\"><strong>Second-Line Agents</strong></h3><ul><li>Under most circumstances, choose ONE of the following second-line agents.  If seizures persist 10-20 minutes after the second-line agent (+/- optimization) finishes infusing, strongly consider advancing to a continuous infusion agent (third-line agent) to improve the likelihood of quickly achieving seizure-control. </li></ul><ul><li> <strong>Fosphenytoin IV load:</strong><ul><li> 20 mg PE/kg (max 1500 mg PE/dose), infused over 15 minutes</li><li> If seizure persists 10 minutes after initial dose is complete, then can consider additional 10 mg/kg load (over 10 minutes) or, if unable to administer second bolus, escalate to third line agent</li><li> Check total phenytoin level 2 hours after the load. Order stat level for 35min turnaround time</li></ul></li></ul><ul><li> <strong>Levetiracetam IV load: </strong><ul><li> Give 60 mg/kg (max 4500 mg/dose), infused over 15 minutes</li><li> If seizure persists 10 minutes after dose complete, then advance to third line agent</li></ul></li></ul><ul><li> <strong>Phenobarbital IV load</strong> (particularly if patient is less than 30 days old):<ul><li>Give 20 mg/kg, (max: 1000mg/dose) infused over 15 minutes</li><li>If seizure persists 10 minutes after dose is complete, then can consider additional 10 mg/kg load (over 10 minutes; max culminative dose: 40mg/kg) or, if unable to administer additional bolus, escalate to third line agent</li><li> Check serum phenobarbital level 2 hours after the load. Order stat level for 35min turnaround time</li></ul></li></ul><ul><li> <strong>Valproate sodium</strong> (Depacon – the IV form of enteral medications such as Depakote, Depakene, divalproate sodium, or valproic acid) IV load (particularly effective in <strong>absence </strong>status epilepticus)<ul><li>40 mg/kg (max 3000 mg/dose) infused over 15 minutes</li><li> Could alternatively give 20 mg/kg dose and repeat if needed, especially if just needs a load to stop break-through seizures</li><li> Avoid in children less than 2 years old unless POLG1 gene status is known</li><li> May cause hyperammonemia</li><li> If seizure persists 10 minutes after dose complete, then advance to third line agent</li></ul></li></ul><h3 id=\"third-line-agents\">Third-Line Agents</h3><ul><li>The following medications administered as continuous infusion should be strongly considered if seizures persist 10-20 minutes after the second-line agent has finished infusing.  Refractory status epilepticus will typically not respond to alternative second-line agents.  Titrate to cessation of electrographic seizures or burst suppression.  In most cases, 24 hours of seizure control is recommended prior to slow withdrawal of continuous infusion. Hypotension is common and should be prepared for.<br><br>&nbsp;<ul><li><strong>Midazolam infusion: </strong><ul><li>Give a 0.1-0.15 mg/kg IV bolus (over 2 minutes) and then begin continuous infusion at 0.1 mg/kg/hr. </li><li> Reassess efficacy every 5-30 mins. If seizures persist, then rebolus 0.1-0.15 mg/kg IV (over 2 minutes) and uptitrate infusion by 0.1 mg/kg/hr to a max rate of 2 mg/kg/hr. </li><li>Can give additional 0.15 mg/kg boluses as needed for breakthrough seizures.</li><li>Consider moving to an alternative infusion if no response is present with midazolam above 0.6-0.7 mg/kg/hr, definitely by 1 mg/kg/hr (max 2 mg/kg/hr)</li></ul></li></ul></li></ul><ul><li> <strong>Ketamine infusion:</strong><ul><li> Give a 2 mg/kg IV bolus (over 5 minutes) and then begin continuous infusion at 0.5-1 mg/kg/hr.</li><li> Reassess efficacy every 30 minutes. If seizures persist, rebolus with 1.5 mg/kg IV and uptitrate infusion with every other bolus by 0.5 mg/kg/h to a max rate of 6 mg/kg/h.</li><li> Can give additional 1.5 mg/kg boluses as needed for breakthrough seizures.</li><li> Reassess every two hours for oversuppression (&lt;1 burst per page on EEG). If oversuppressed, decrease the infusion rate by 10-20%</li><li> Consider moving to an alternative infusion if no response is present with ketamine above 6 mg/kg/hr</li></ul></li></ul><ul><li> <strong>Pentobarbital infusion: </strong><ul><li> Give a 2-5 mg/kg IV bolus (over 15 minutes) and then begin continuous infusion at 0.5 mg/kg/hr. </li><li>Reassess efficacy every 30 minutes. If seizures persist, then rebolus in aliquots of 1-2mg/kg (infused over 10-15 minutes) and increase infusion by 0.5 mg/kg/hr</li><li>To avoid oversuppression, uptitrate continuous infusion sparingly (i.e. with every other bolus maximum) to a max rate of 5 mg/kg/hr. </li><li>Can give additional 1-2 mg/kg boluses as need for breakthrough seizures.</li><li>Administration of repeated, small bolus doses of pentobarbital is the most effective strategy to achieve burst suppression during coma induction and can facilitate the use of lower infusion rates/doses, which may avoid oversuppression and unnecessarily prolonged coma (Krishnamurthy 1999, Schreiber 2011).   </li><li>Contains a sugar alcohol (i.e., cannot achieve ketosis during infusion)</li></ul></li></ul><ul><li> <strong>Propofol infusion (DO NOT REC WITHOUT DISCUSSION btwn Neuro &amp; ICU attendings): </strong><ul><li> Give a 2 mg/kg IV bolus (over 1-5 minutes) and then begin continuous infusion at 20 mcg/kg/min. </li><li>Reassess efficacy every 5-30 minutes. If seizures persist, then rebolus with 0.5-1 mg/kg IV and uptitrate infusion by 10-20 mcg/kg/min to a max rate of 67 mcg/kg/min.</li><li>Can give additional 0.5-1 mg/kg boluses as needed for breakthrough seizures.</li><li>Propofol associated hypotension is dose dependent and more likely when administering larger or repeated bolus doses.</li><li>If a patient arrives from an outside institution appropriately controlled on propofol, consider continuing for up to 24 hours.</li><li>To minimize risk of propofol infusion syndrome:<ul><li>·       Infusion duration should be as short as possible, and the dose should not exceed 67 mcg/kg/min (Cornfield 2002). If more than 24 hours required, then need to assess risk/benefit ration and inform parents/guardians.</li><li>·       Serial blood gas monitoring may be helpful to monitor for a developing metabolic acidosis as an early indication of possible propofol infusion syndrome.</li></ul></li></ul></li></ul><h2 id=\"general-suggestions-on-how-to-wean-continuous-infusions\">&nbsp;General suggestions on how to wean continuous infusions</h2><p>There are no data on the appropriate timing or rate of tapering continuous infusions in the treatment of refractory or super-refractory status epilepticus.  Generally speaking, coordinate with attending and primary team, weaning is typically 24-48 hours after cessation of seizures.  </p><p>·       Midazolam – decrease 0.1 mg/kg/hour every 1-3 hours</p><p>·       Ketamine – decrease 1 mg/kg/hour every 1-3 hours</p><p>·       Pentobarbital – decrease 1 mg/kg/hour every 1-3 hours</p><p>·       Propofol – decrease by 50% for 1-3 hours then discontinue</p><h2 id=\"general-suggestions-on-how-to-wean-continuous-infusions-2\">General suggestions on how to wean continuous infusions</h2><p>There are no data on the appropriate timing or rate of tapering continuous infusions in the treatment of refractory or super-refractory status epilepticus.  Generally speaking, coordinate with attending and primary team, weaning is typically 24-48 hours after cessation of seizures.  </p><ul><li>Midazolam – decrease 0.1 mg/kg/hour every 1-3 hours</li><li>Pentobarbital – decrease 1 mg/kg/hour every 1-3 hours</li><li>Ketamine – decrease 1 mg/kg/hour every 1-3 hours</li><li>Propofol – decrease by 50% for 1-3 hours then discontinue</li></ul><p><strong>Adjunctive Therapies</strong></p><p>Can be utilized in parallel with above treatments and in preparation for withdrawal of continuous infusion agents. Additional <strong>second-line agents</strong> (IV loads +/- maintenance dosing):</p><p><strong>Valproate sodium:</strong></p><p>·       20-40 mg/kg IV load (infused over 15 minutes)</p><p>·       Can be particularly helpful in patients on valproic acid (Depakote or Depakene) maintenance with subtherapeutic levels. </p><p>·       Check serum valproate concentration 2-3 hours after the load.</p><p>·       Consider starting maintenance at 15 mg/kg/day divided q6hours, 12 hours after the load.</p><p>·       Avoid in children less than 2 years old unless POLG1 gene status is known</p><p>·       May cause hyperammonemia.</p><p><strong>Lacosamide:</strong></p><p>·       4 mg/kg IV load (max 300 mg), infused over 15 minutes</p><p>·       Consider starting maintenance at 3-5 mg/kg/day divided BID, beginning 12 hours after the load.</p><p>·       Max 10 mg/kg/day</p><p><strong>Topiramate:</strong></p><p>·       4-8 mg/kg enteral load (max 400 mg)</p><p>·       Typically start maintenance at 3-5 mg/kg/day divided BID, beginning 12 hours after the load. </p><p>·       Uptitrate by 2-5 mg/kg/day every 2-7 days to a max of 10-15 mg/kg/day.</p><p>·       May cause a metabolic acidosis.</p><p><strong>Magnesium Sulfate:</strong></p><p>·       25-50 mg/kg IV (Max 2 grams) infused over 30 minutes</p><p>·       Consider for patients with POLG1 mutations.</p><h2 id=\"electroencephalogram-eeg\">Electroencephalogram (EEG)</h2><ul><li>An EEG should be ordered STAT after failure of the second-line agent to assess for subclinical seizure activity and to assist in medication titration.</li><li>Titrate to cessation of electrographic seizures or burst suppression, which will be determined by discussion between neurology and critical care teams.  In most cases, if a continuous infusion was required, 24 hours of seizure control is recommended prior to slow withdrawal of continuous infusion.</li><li>Reassess every two hours for oversuppression (&lt;1 burst per page on EEG). If oversuppressed, decrease the infusion rate by 10-20%.</li></ul><h2 id=\"other-considerations-in-management\">Other considerations in Management</h2><h2 id=\"supportive-care-goals\">Supportive Care Goals</h2><ul><li>Intubation and mechanical ventilation if GCS 3-8 </li><li>Target normocapnea (PaCO2 40-45) </li><li>Target normal BP for age. Avoid hypotension.  Assure good intravascular volume.  Be prepared for hypotension with continuous infusion agents and order vasopressor(s) to bedside). </li><li>Avoid treatment of hyPERtension until seizures have stopped.</li><li>Maintain normal systemic and cerebral perfusion</li><li>Cerebral autoregulation is frequently impaired during prolonged (&gt;20-30 min) SE</li><li>HOB at 30° </li><li>Target normothermia (36.0°C-37.5°C) </li><li>Consider scheduled antipyretics </li><li>If using a cooling blanket, control shivering per TTM order set recommendation</li><li>Target normal serum sodium concentration (136-145) </li><li>Target normal serum glucose concentration (80-180) </li><li>Target early enteral nutrition via naso-enteric feeding tube with goal to initiate enteral feeds within 48 hours of admission.</li></ul><h2 id=\"diagnostic-work-up-management-of-underlying-causes-of-status\">Diagnostic work-up/management of underlying causes of status epilepticus</h2><p><strong>Most common causes of status epilepticus:</strong></p><p><strong>In patients with known seizures or epilepsy:</strong>  breakthrough seizure, missed medication, and illness.  Thus, patients with known seizures may not require extensive work-up; however, work-up should always be tailored to the individual patient. </p><p><strong>In patients with new onset status epilepticus:</strong> hypoglycemia, electrolyte disturbances, drug/toxin ingestion, intracranial pathology (such as intracranial hemorrhage, stroke, or tumor), CNS infection, and undiagnosed epilepsy.  </p><p>Screen for fever, illness, dehydration, exposure, ingestion, or trauma. If signs or symptoms noted on physical exam and history are suggestive of a provoking etiology, consider the evaluations below.</p><p><strong>Hypoglycemia – ANY patient is at risk for hypoglycemia</strong></p><p>Check blood glucose and correct if less than 60 mg/dL (5 ml/kg D10)</p><p>Consider empiric Thiamine 20 mg/kg/day IV prior to dextrose if at risk of nutritional deficiencies</p><p><strong>Electrolyte Disturbances – Particularly important to consider for infants and patients with recent vomiting, diarrhea, or poor PO intake.</strong></p><p>Check BMP to assess for hyponatremia or hypocalcemia.  </p><p>Correct hyponatremia carefully if felt to be present for more than a few hours (goal to increase to 120 meq/l quickly then slowly increase by &lt; 8-12 meq/l/day) to mitigate risk of central pontine myelinolysis. </p><p>Correct hypocalcemia with calcium gluconate (or calcium chloride if CVL in place) and consider assessing for concurrent hypomagnesemia.</p><p><strong>Drug/toxin ingestion – Consider in patients with possible exposure</strong></p><p>UTox, serum tox, salicylate, acetaminophen, and ethanol levels</p><p>Blood gas to evaluate for metabolic acidosis, which could suggest ingestion</p><p><strong>Intracranial pathology - Strongly consider for infants, patients with concern for head trauma or significant fall, patients with focal seizure, patients with focal neurologic deficits, patients with signs of increased intracranial pressure, and patients with poor return to baseline after cessation of seizure activity</strong></p><p>Consider emergent non-contrast head CT or rapid MRI brain protocol</p><p>If patient with known epilepsy or prior febrile seizures AND a recent fall/head trauma or infection, consider head CT or rapid MRI brain protocol to assess for new acute pathology. </p><p><strong>Infectious Evaluation – if patient is febrile or clinical history is suggestive of infection</strong></p><p>Obtain blood, urine, respiratory cultures</p><p>If head CT/MRI is negative, consider lumbar puncture</p><p>Please obtain serum glucose at same time as LP</p><p>Consider viral PCRs and bacterial culture</p><p>Consider sending CSF multiplex encephalitis panel testing </p><p>In patients with CNS hardware, also consider slow-growth bacterial cultures</p><p>Consider empiric antibiotics (meningitic doses) and/or acyclovir if high suspicion or new-onset SE with fever</p><p>Surveillance cultures (Blood, Urine and Tracheal) recommended every 24 hours if temperature controlled or on Pentobarbital infusion </p><p><strong>Metabolic Evaluation</strong></p><p>Consider the following, as indicated by history and physical exam:</p><p>·       LFTs, ammonia, ASM levels, urine/serum toxicology screens</p><p>·       Metabolic screen (lactate, pyruvate, CK, serum amino acids, urine organic acids, carnitine, acylcarnitine)</p><p>·       Comprehensive CSF studies (infectious and autoimmune encephalitis workup, lactate, pyruvate)</p><p>·       Autoimmune serum labs (thyroid antibodies, anti-GAD, NMDA, VKCC, paraneoplastic and/or autoimmune encephalitis panels)&nbsp;</p><h1 id=\"neonatal-seizures\">Neonatal Seizures</h1><ul><li>Neonates typically do not have generalized seizures because their myelination is immature (ie, they are more likely to have focal seizures).</li><li>Apneic spells may or may not be seizure. </li></ul><p><strong>Neonatal seizure etiologies </strong>(Rough timing guidelines—any of these can present at any time)</p><div class=\"table-wrap\"><table><thead><tr><th><p><strong>&lt; 24 hours</strong></p></th><th><p><strong>24-72 hours</strong></p></th><th><p><strong>72hr-1 week</strong></p></th></tr></thead><tbody><tr><td><p>HIE</p></td><td><p>Infarction</p></td><td><p>Metabolic</p></td></tr><tr><td><p>Meningitis/sepsis</p></td><td><p>Venous clot</p></td><td><p>HSV</p></td></tr><tr><td><p>Blood: SDH, SAH, IVH</p></td><td><p>IVH</p></td><td><p>Hypocalcemia</p></td></tr><tr><td><p>TORCH</p></td><td><p>Meningitis/sepsis</p></td><td><p>Benign neonatal convulsion</p></td></tr><tr><td><p>Pyridoxine dependence</p></td><td><p>Structural abnormality</p></td><td></td></tr><tr><td><p>Drugs/withdrawal</p></td><td></td><td></td></tr></tbody></table></div><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Ischemia/hypercoaguability</strong></p></td><td><p><strong>Toxic</strong></p></td></tr><tr><td><p>Hypoxic-ischemic Encephalopathy</p><p>Focal ischemic stroke</p><p>Sinus Venous Thrombosis</p></td><td><p>Direct Drug effect</p><p>Drug withdrawal</p></td></tr><tr><td><p><strong>Hemorrhage</strong></p></td><td><p><strong>Inborn Error of Metabolism</strong></p></td></tr><tr><td><p>Intraventricular Hemorrhage</p><p>Subarachnoid Hemorrhage</p><p>Subdural hemorrhage with contusion</p><p>Intracerebral hemorrhage</p></td><td><p>Urea Cycle disorders</p><p>Glycogen storage disorder</p><p>Aminoacidopathy</p><p>Lysosomal storage or Peroxisomal disorders</p><p>Mitochondrial disorders</p></td></tr><tr><td><p><strong>Infection</strong></p></td><td><p><strong>Metabolic</strong></p></td></tr><tr><td><p>Meningitis/Encephalitis</p><p>Viral: HSV     OR      Bacterial</p><p>Intrauterine infection</p></td><td><p>Hypoglycemia</p><p>Hypocalcemia/hypoparathyroidism</p><p>Kernicterus</p></td></tr><tr><td><p><strong>Malformation</strong></p></td><td><p><strong>Genetic</strong></p></td></tr><tr><td><p>Cortical dysplasia </p><p>Cerebral dysgenesis/Lissencephaly</p><p>Holoprosencephaly</p></td><td><p>Familial neonatal seizures </p><p>Benign Idiopathic Neonatal Seizures (5<sup>th</sup> day fits)</p><p>Ohtahara, Early Myoclonic Encephalopathy</p><p>Syndromes: Rett, Angelman</p></td></tr></tbody></table></div><p><strong>Evaluation</strong></p><p><em>Laboratory Studies</em></p><div class=\"table-wrap\"><table><thead><tr><th><p><strong>Acute</strong></p></th><th><p><strong>Next step</strong></p></th><th><p><strong>Consider</strong></p></th></tr></thead><tbody><tr><td><p>CMP, mag, phos, calcium</p></td><td><p>CSF Neurotransmitters</p><p>        Aminoacids</p><p>        Lactate/pyruvate</p></td><td><p>TORCH titers</p></td></tr><tr><td><p>Utox</p></td><td></td><td><p>Rett </p></td></tr><tr><td><p>Ammonia</p></td><td></td><td><p>Very long-chain fatty acids</p></td></tr><tr><td><p>LP routine with HSV PCR</p></td><td><p>Metabolic work up </p></td><td></td></tr></tbody></table></div><img src=\"/images/epilepsy/img-22.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-21.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p>Neuro-imaging—depends on how stable – consider Head U/S, CTH and brain MRI</p><ul><li>Head U/S can miss subdural bleed but gives detail for brain parenchyma and can see IVH</li><li>HCT for blood, high water content of neonatal brain can cause false normalization with stroke</li><li>MRI to evaluate for structural lesions, HIE, perinatal stroke</li></ul><p><strong>Management</strong></p><p>Treat identifiable causes – otherwise see below.</p><h1 id=\"neonatal-seizure-algorithm\">Neonatal Seizure Algorithm</h1><ul><li><strong>Phenobarbital and fosphenytoin levels (guidelines, always refer to attending): </strong></li></ul><p>Neonates:</p><p>Fosphenytoin level (ref 10-20 ug/ml):</p><p>-       If less than &lt; 10, give 15-20 PE/kg load</p><p>-       If 10-16, give 10 PE/kg load</p><p>-       If &gt; 16, give another agent</p><p>Phenobarbital level (ref 15 - 40 mcg/ml):</p><p>-       If &lt; 20, give 20 mg/kg load</p><p>-       If 20-35, give 10 mg/kg load</p><p>-       If &gt;35, give another agent</p><h2 id=\"iv-pyridoxine-vitamin-b6-challenge\">IV Pyridoxine (vitamin B6) challenge</h2><ul><li>Use 100mg pyridoxine IV to be pushed over 1-3 minutes. It can also be slowly infused in over 15-30 min as IV push may cause burning</li><li>If no clinical response, the dose should be repeated up to a maximum of 500 mg, although corresponding change on EEG may be delayed by several hours</li><li>Have patient on CR monitor, cEEG, and vitals q 5 minutes</li><li>Provider should be at the bedside during the injection/push and 5-10 min after injection to watch for any SEs (risk of apnea, cardiorespiratory depression, profound sedation) and to look at EEG monitoring.</li><li>Can alternatively begin supplementation with 30 mg/kg/day of pyridoxine while awaiting gene testing (less risk of hemodynamic instability than the IV challenge)</li><li>Should have seizure resolution within 3-7 days once pyridoxine supplementation has started</li></ul><h1 id=\"home-seizure-rescue\">Home Seizure Rescue</h1><h2 id=\"home-rescue-for-prolonged-seizure\">Home Rescue for prolonged seizure:</h2><ul><li>Rectal diazepam (Diastat)</li><li>Intranasal midazolam, prefilled (Nayzilam)</li><img src=\"/images/epilepsy/img-15.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><li>Intranasal diazepam, prefilled (Valtoco)</li></ul><div class=\"table-wrap\"><table><tbody><tr><td><p>Weight in kg</p></td><td><p><strong>Intranasal midazolam</strong></p><p><strong> 0.2-0.3 mg/kg Dose = volume</strong></p></td><td><p><strong>For school/ seizure action plan</strong></p></td></tr><tr><td><p>3–5 kg</p></td><td><p>1 mg = 0.2 mL total</p><p>0.1 mL per nostril</p></td><td><p><strong>Diastat</strong>: use Diastat dosing chart</p></td></tr><tr><td><p>6-9 kg</p></td><td><p>2 mg = 0.4 mL total</p><p>0.2 mL per nostril</p></td><td><p><strong>Diastat</strong>: use Diastat dosing chart</p></td></tr><tr><td><p>10–15 kg</p></td><td><p>3 mg = 0.6 mL total</p><p>0.3 mL per nostril</p></td><td><p><strong>Diastat</strong>: use Diastat dosing chart</p></td></tr><tr><td><p>16-26 kg</p></td><td><p>5 mg = 1 mL total</p><p>0.5 mL per nostril</p></td><td><p>May prescribe <strong>midazolam</strong> at 1mL total</p></td></tr><tr><td><p>27–32 kg</p></td><td><p>8 mg = 1.6 mL total</p><p>0.8 mL per nostril</p></td><td><p><strong>Diastat:</strong> use Diastat dosing chart</p></td></tr><tr><td><p>&gt;=33kg</p></td><td><p>10 mg = 2 mL total</p><p>1 mL per nostril</p></td><td><p>May prescribe <strong>midazolam</strong> at 2mL total</p></td></tr></tbody></table></div><img src=\"/images/epilepsy/img-14.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-9.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-16.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><h1 id=\"bridging-sick-kids-with-benzos\">Bridging Sick Kids with Benzos</h1><p>Bridging Sick Kids with Benzos*</p><p>Clonazepam 0.01-0.03mg/kg/day divided BID x 3-5 days </p><p>Formulations:</p><p>·       ODT: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</p><p>·       Tabs:  0.25mg; 0.5mg; 1 mg tabs</p><p>·       Solution: 0.1 mg/mL</p><p>* This approach is less effective in patients taking clobazam.  In this case, you can also consider using extra dose of maintenance medication.</p><p><strong>IF you need to convert benzodiazepines, 20mg clobazam = 0.5mg clonazepam.  Also see:  </strong><a href=\"http://www.benzo.org.uk/bzequiv.htm\"><strong>http://www.benzo.org.uk/bzequiv.htm</strong></a></p><h1 id=\"eeg-reading-basics\">EEG Reading Basics</h1><div class=\"table-wrap\"><table><tbody><tr><td></td><td></td></tr><tr><td></td><td><p>Sleep Stages</p><p>Stage W: Wakefulness</p><p>Drowsiness: Fluctuation in alpha rhythm, general fronto-central slowing, overall loss of voltage</p><p>Stage N1: Vertex waves, positive occipital sharp transients of sleep (POSTS)</p><p>Stage N2: Spindles and K complexes (vertex waves can persist)</p><p>Stage N3: Slow wave sleep.  Appearance of delta activity (spindles can persist)</p><p>Stage R:  REM sleep. Low-voltage fast activity with no alpha, rapid lateral eye movements</p></td></tr></tbody></table></div><p><strong>Neonatal EEG Normal Waveforms                    </strong></p><img src=\"/images/epilepsy/img-19.gif\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><h3 id=\"helpful-tips\">Helpful Tips:</h3><p><strong>General</strong></p><p>·       For questions regarding EEGs while on call, first consult with the primary attending, then call epileptologist for further assistance if necessary.</p><p>·       In patients with complex EEGs, consider reviewing prior studies to look for likeness (especially helpful with LGS).  The EEG techs can pull old studies for review by request.</p><p>·       Arousal patterns in young children can be mistaken for seizure.  For sudden high amplitude, semi-rhythmic activity starting out of sleep, watch video to r/o arousal pattern.</p><p><strong>Neonatal EEG</strong></p><p>·       Neonatal EEG can usually be read easier when condensed at a faster paper speed (15/sec).</p><p>·       Patting and sucking artifact is common. If neonatal seizures are considered, video must be present and reviewed.</p><p>·       Neonatal seizures can occur in only one channel and be very low voltage.</p><p>·       Typically needs to last for a minimum of 10 seconds to be considered a seizure, otherwise a BRD (brief rhythmic discharge), unless a clinical correlate</p><p><strong>Using XLTEK</strong></p><p>·       Annotation of the EEG is performed by simply typing while reviewing a record.  Do so for events you would like to be reviewed later, to know what time you last reviewed, or even to record a brief impression of the record.</p><p>·       Can use the Seizure and ? Seizure buttons to mark the EEG as well, this will also allow you to note duration of events</p><p>·       Remember to use your notch filter.</p><h1 id=\"ketogenic-diet\">Ketogenic Diet</h1><p>High fat (80-90%), adequate protein, limited carbs</p><p><strong>Efficacy</strong></p><ul><li>Neal 2008 random prospective trial 38% of pts had &gt; 50% reduction in seizures, 7% sz free, compared to 6% controls and zero sz free.</li><li>John Hopkins 1997: 7% seizure free, 20% with &gt;90% reduction in seizures, 50% with &gt;50% reduction in seizures after 1 year</li><li>Freitas 2007: 54 children. 57% &gt;75% seizure control.</li><li>Henderson: pts stopped diet b/c had &lt; 50% seizure reduction, 16% diet restrictions and 13 % had SEs</li><li>Cochrane review 2016: rates of seizure freedom reached as high as 55% in 4:1 KD group after three months and reported rates of seizure reduction reached as high as 85% in 4:1 KD group after three months</li></ul><p><strong>Type of szs/syndromes</strong>:</p><p>·       GLUT-1 transporter deficiency (first-line treatment)</p><p>·       Any seizures especially tonic, atonic, atypical absence</p><p>·       Infantile spasms</p><p>·       Dravet</p><p>·       Doose/Epilepsy with Myoclonic-Atonic Seizures</p><p>·       FIRES.</p><p>·       <strong>Epileptologist consultation is needed prior to referring a patient for the ketogenic diet</strong>.</p><p><strong>Micronutrient deficiency</strong>:</p><p>·       Need MVI/calcium/vit D supplementation</p><p>·       Deficiencies include carnitine, Zn, Selenium, vit D, K, Phos, fiber, bicarb</p><p><strong>SEs</strong>:</p><p>·       Kidney stones</p><p>·       Constipation</p><p>·       Increased lipids</p><p>·       Decreased growth</p><p>·       Acidosis</p><p>·       Weight loss</p><p>·       GERD</p><p>·       Other SEs: osteopenia, anemia, prolonged QT, cardiomyopathy, pancreatitis, hypoproteinemia, leukopenia<br><br>&nbsp;</p><p><strong>Preketogenic labs:</strong> CMP, CBC, lactate/pyruvate, urine organic acids, serum amino acids, acylcarnitine profile, phosphorous, fasting lipid panel, carnitine, 25OH vit D, Mg, Zn, Selenium </p><p><strong>Hospitalization – not always required, per keto team and epileptologist discretion</strong>:</p><p>·       Monday admission (9 AM) to EMU.</p><p>·       Patients do not need to fast for this admission. </p><p>·       Non caloric beverages only (on admission, anyway), formula options (RCF, Ketocal 3:1 or 4:1). </p><p><strong>Day one fasting labs</strong>: BMP and lipids; liquid diet for first day for 100% of calories.</p><p><strong>On call issues:</strong></p><p><strong>Basic principles:</strong>  <strong>Maintain ketosis! Avoid carbs.</strong></p><p>Avg Bicarb 18-23, BS 50-80 (if on TPX/ZGN may have lower bicarb)</p><p>·       Try to eat all meals (even if ill) to maintain ketosis &amp; avoid hypoglycemia</p><p>·       Drink all assigned fluids (even if ill) to avoid dehydration (0 kcal, 0 caffeine except fluids used in meal/snack plans)</p><p><strong>FAQs</strong></p><p>·      <strong>If a child eats food with high carbohydrate content:</strong></p><p>·      Continue current ratio, do not fast unless authorized by attending and only after education has been provided to family</p><p>·      Try adding a little extra fat (ie tablespoon of butter or oil) for orally fed kids, for g-tubers, just continue keto formula</p><p><strong>Illness/ refusal to eat/loss of ketones in urine:</strong></p><p><strong>If vomited or won’t eat, give ½ meal quantity &amp; double the number of meals per day</strong></p><p>·       If still refusing/vomiting, try smaller meals or liquid ketogenic replacement (can sip small amounts all day as the ratio is the same in each sip)</p><p>·       If refusing to take anything, try carb replacement liquid 1½-2 oz OJ or apple juice up to every 4 hours.</p><p>·       Pedialyte is okay (but has less carb and will require more volume)</p><p>·       Encourage intake of prescribed quants of 0 calorie/caffeine fluids</p><p><strong>If child is becoming dehydrated</strong></p><p>·       Increase fluid intake to 1 ½ maintenance</p><p>·       If still concerned seek medical attn (PCP/ED)</p><p>·       Advise to bring Paramedic/ED letter with diet specifications</p><p>·       If needs continuous fluids and BS &gt;40 no dextrose, NS only for bolus</p><p>·       If BS &lt; 40 give 4-5 grams dextrose, repeat BSs w/ goal 40-80</p><ul><li>If D5W there are 5 grams of dextrose per 100 cc IV</li><li>If D10W, there are 10 grams of dextrose per 100 cc</li><li>Do not give anything &gt;10% through peripheral IV</li></ul><p>·       Ketones will return to pre-illness levels after recovery</p><p>·       If c/o back/abd pain w/ or w/o dark/bloody urine, inconsolable suspect kidney stone. If found/suspected inc fluids to 130+% maintainence, try cytra K</p><p>·       If severe pain/emesis +/- fever, consider dx of pancreatitis and urgent evaluation.</p><p><strong>Concomitant Medication Issues:</strong></p><p>·       Tabs, caps, IM, IV, rectal, nasal drops, sprays, nebulizers—all okay</p><p>·       Chewables, oral suspensions/liquids/elixirs—avoid (use only if no substitute)</p><p>·       <strong>Acceptable fever/pain meds and dosages</strong>: brand name Tylenol 325 tabs and caps, 500 caps, Feverall rectal suppositories 80, 120, 325. Children’s junior Motrin 100 caps, Advil 200 caps, 100 mg/5 mls (use sparingly as this has some carbs).</p><p><strong>Increased seizures or seizure after seizure free period</strong></p><p>·       Evaluate same as if not on diet (missed meds, illness, recent change in antiseizure meds, or doses.</p><p>·       Keto questions:</p><ul><li>Have ketones dropped? if so, consider illness, prodrome of illness and c below.</li><li>Any change in diet ratio or calories recently?</li><li>Has child gotten high carb food (any new foods or meds)?</li><li>Is he/she ill?</li></ul><p>·       What time are they measuring ketones? AM ketones are typically lower than PM ketones</p><p>·       Potential intervention</p><ul><li>Remove hidden carb food or change med form (tab or cap which can be opened up)</li><li>Revert back to former calorie or ratio, or med change</li><li>Use intranasal midazolam, rectal diastat if needed</li></ul><p><strong>Issues when a child on the keto diet is admitted for medical problems</strong></p><p>·       <strong>*Any child on keto who is admitted for any reason for &gt; 24 hours should be transferred to main campus for keto support*</strong></p><p><strong>Dehydration:</strong></p><p>·       If unable to tolerate po fluids, IV hydration necessary</p><p>·       Should use routine non-dextrose fluids as you would do for any child</p><p>·       No dextrose to maintenance fluids</p><p><strong>NPO</strong></p><p>·       Keto kids should not be NPO for more than 12-13 hours, unless blood sugars are monitored. Monitor glucose q 4 hours while NPO.</p><ul><li>Monitor glucose with bedside glucometer every q 1 hour while NPO.</li></ul><p>·       Metabolic kids should not be fasting more than 8 hours without calories and consult genetics/metabolics</p><p>·       Easiest: give child a meal/full replacement liquid meal just before NPO. Give carb clear liquid replacement until 2 hours before scheduled test (if allowed)</p><p>·       Monitor glucose and for sxs of hypoglycemia</p><p>·       Carbs cannot be given for 8 hours before, even if not NPO for sedation, can only have water.</p><p>·       In children with metabolic disorders, fluid management should be deferred to the metabolic team.</p><p><strong>Child is admitted for other medical/surgical problems</strong></p><p>·       How to convert NPO or clear liquids or diet as tolerated to ketogenic diet acceptable fluids/meals: Juice/soda/pedialyte to ketogenic egg nog or liquid replacement meal to full solid meals</p><p>·       Child should eat all of meal or replacement meal to maintain ketosis/prevent hypoglycemia</p><p>·       Check blood glucose at least once</p><p>·       Addition concomitant meds including pain mgt: oral meds must have minimal CHO</p><p>Check urinary ketones at least once and consider BHB</p><p><strong>Child is admitted in the middle of the night</strong></p><p>·       If you decide to keep the child on the diet, can the diet be maintained po/gt? If yes, any IVF should be without dextrose</p><p>·       If child is NPO, options include:</p><ul><li>IV without carbs and give dextrose (juice) if BS drops below acceptable level. Monitor blood sugar fingersticks: <strong>keep glucose &gt;40 and &lt;80</strong></li><li>Give continuous acceptable quantities of IV dextrose</li><li>Monitor blood sugar levels: keep glu 40-80</li><li>Give 5% dextrose by IV diluted with saline (use pharmacy to help)</li><li>Start with maximum initial infusion of 1-2 grams per hour until BS &gt;40</li><li>Titrate carb/hr based upon blood sugar parameters</li></ul><h1 id=\"vagus-nerve-stimulator-vns\">Vagus Nerve Stimulator (VNS) </h1><ul><li>VNS is not a cure. The VNS is used to help control or lessen the severity of seizures.  VNS is discussed prior to implantation at the epilepsy surgery conference to determine eligibility.</li></ul><p><strong>Basics for parents</strong></p><p>·       The generator is implanted under the skin of the chest and electrodes are wrapped about the left vagus nerve in the neck. </p><p>·       A stimulus is sent to the vagus nerve at programmed intervals to attempt to prevent seizures and family can use a magnet to activate the device at higher settings to try to abort a seizure.  Newer devices (106 and Sentiva) monitor heart rate and will generate a slightly higher current for rapid changes in heart rate that may be associated with seizures.</p><p>·       VNS is activated just after implantation and ramped up per a protocol with a combination of neurology clinic visits and preprogramming for automatic ramps (for Sentiva only!) every 1-2 weeks.</p><p>·       The battery lasts 6-10 years and must be surgically replaced. We do not remove the lead on the vagus nerve due to risk of injury.</p><p><strong>During active seizures</strong></p><p>·       Swipe the magnet over the generator for a count of 3 seconds. </p><p>·       Once the magnet is removed from the generator, the generator will provide a higher amplitude pulse to the nerve for 60 seconds to try to abort the seizure or shorten the postictal period. </p><p>·       Magnet can never be used too much or hurt the device by using the magnet in any way. The VNS can only be activated every 60 seconds regardless of how much you swipe it.</p><p><strong>Side effects</strong></p><p>·       Local discomfort, throat pain, cough, changes of voice pitch and volume, as well as reflux.</p><p>·       These side effects can usually be modulated by changing the VNS settings. </p><p>·       If a patient reports intolerable side effects to stimulation, have them place the magnet over the generator and put heavy tape over the magnet to keep it in place.  As long as the magnet remains over the generator, the device is off and no current will be delivered to the nerve. When the magnet is removed, the device will resume previous stimulation parameters.</p><p>·       OSA can be an adverse effect of VNS. Increased excessive daytime sleepiness or worsening snoring should be evaluated with a PSG.</p><p><strong>VNS Considerations</strong></p><p>·       The lead of the VNS is ferromagnetic and may heat up in the presence of a strong magnetic field, such as an MRI. MRI should not be performed of the chest and upper spine.</p><p>·       VNS should be “turned off” prior to MRI by having the output current set to zero. This can be performed by the EEG technologists or Advance Practice Providers in the EMU for inpatients or by RNs in clinic for regularly scheduled MRI.</p><p>·       The VNS device can be affected by electrocautery during surgery. As such, the device should be <strong>interrogated before and after surgery to ensure that it is functioning appropriately. </strong>OR requests that the device be turned off prior to surgery and the turned back on after surgery.</p><h1 id=\"infantile-spasms\">Infantile Spasms</h1><p>Infantile spasms (IS) is an epilepsy of early infancy, affecting 3-4.5/10,000 live births, with typical onset 1-15 months (peak 4-9 months), M&gt;F.  Often associated with developmental issues.</p><p>Patients can have flexor, extensor, mixed flexor-extensor, and/or asymmetric spasms.  IS can mimic reflux or myoclonus.  Patients are often admitted for continuous EEG to definitively evaluate for infantile spasms.</p><img src=\"/images/epilepsy/img-20.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p><strong>Etiology</strong></p><p>Unknown etiology (30%).     Known etiology (70%) - Over 200 causes, such as:</p><div class=\"callout-box\"><p><strong>Some conditions more likely to predispose to IS (alphabetically)</strong></p>\n<p>Aicardi syndrome, Abusive head trauma, ARX mutation, Cytomegalovirus (CMV), Hemimegalencephaly, Hypoxic Ischemic encephalopathy (HIE), Incontinentia pigmenti, Lissencephaly, Phenylketonuria (PKU), Sturge Weber, Trisomy 21, Tuberous sclerosis complex (TSC)</p></div><p><strong>Diagnosis of IS                    </strong></p><p>The diagnosis of infantile spasms requires EEG evidence of interictal hypsarrhythmia (random/chaotic high-voltage slow waves and spikes, arising from multiple foci), modified hypsarrhythmia, or ictal EEG manifestations of infantile spasms (brief/rapid sharp wave, then high amplitude delta with superimposed low voltage fast activity, followed by electrodecrement lasting seconds). </p><p>·       Not all patients with IS have hypsarrhythmia.</p><p>·       EEG should be of sufficient duration to include wake and sleep to rule out a diagnosis of infantile spasms.</p><p>·       Consider repeat EEG with sleep/wake cycle in 3-5 days if no episodes are captured and if clinical suspicion remains high despite normal EEG.</p><p>·       Hypsarrhythmia grading: BASED 2021 scoring (Mytinger, et al, 2021)</p><img src=\"/images/epilepsy/img-10.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-11.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-12.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-41.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>2021 BASED Score</strong></p></td><td><p><strong>Description</strong></p></td></tr><tr><td><p><strong>0</strong></p></td><td><p>Normal</p></td></tr><tr><td><p><strong>1</strong></p></td><td><p>Any definite nonepileptiform abnormality</p></td></tr><tr><td><p><strong>2</strong></p></td><td><p>&lt;3 spike foci <strong>AND</strong> no channel with abnormal high amplitude</p></td></tr><tr><td><p><strong>3</strong></p></td><td><p>&gt;3 spike foci &lt;50% of one second bins <strong>AND</strong> no channel with abnormal high amplitude, <strong>OR</strong></p><p>&lt;3 spike foci but &gt;1 channel with abnormal high-amplitude</p></td></tr><tr><td><p><strong>4</strong></p><p><strong>(Probable EE)</strong></p></td><td><p>&gt;3 spike foci &lt;50% of one second bins <strong>AND</strong> &gt;1 channel with abnormal high amplitude, <strong>OR</strong></p><p>Not meeting criteria for 5 but includes GMFS or paroxysmal voltage attenuations</p></td></tr><tr><td><p><strong>5</strong></p><p><strong>(Definite EE)</strong></p></td><td><p>&gt;3 spike foci that are &gt;50% of one second bins</p></td></tr></tbody></table></div><img src=\"/images/epilepsy/img-51.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-50.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-49.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-48.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-47.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-46.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-45.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-44.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-43.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-42.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-37.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-36.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-23.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p><strong>Evaluation after IS diagnosis is made:        (Wirrell et al Epilepsia 2015)</strong></p><img src=\"/images/epilepsy/img-18.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-13.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p>·       Hospital admission for workup and treatment initiation.</p><p>·       Screen for signs/symptoms of illness and tuberculosis risk factors.</p><p>·       MRI brain to evaluate for TS which would change treatment (ie use of vigabatrin)</p><p>·       Obtain epilepsy gene panel if not already done (Behind the Seizure through Invitae is free for children with seizures less than 8 years of age)</p><p><strong>Prognosis: </strong></p><p>·       Resolution of spasms is associated with better developmental outcomes.  The primary driving factor for resolution of spasms is treatment with a standard first-line therapy (ACTH, prednisolone, or vigabatrin). </p><p>·       In children with known etiology, prognosis is related to etiology.  Children without prior developmental delay or prior seizures may have a better prognosis.</p><p>·       Epilepsyà 50-60% develop other seizure types in the future, about 35% develop Lennox-Gastaut syndrome.</p><h2 id=\"treatment-choices\">Treatment choices:  </h2><p>(See Infantile Spasms Clinical Pathway for full details)</p><div class=\"table-wrap\"><table><thead><tr><th></th><th><p><strong>Pros</strong></p></th><th><p><strong>Cons</strong></p></th></tr></thead><tbody><tr><td><p><strong>ACTH    </strong></p><p><strong>(Adrenocorticotropin</strong></p><p><strong>Hormone; Corticotropin; Acthar gel)</strong></p></td><td><p>Likely most effective</p></td><td><p>Adverse effects: Immune suppressant, edema, gastric bleeding, weight gain, irritability, sleep disturbance, HTN, cortical atrophy, HPA axis suppression, death</p><p>Intramuscular injection.</p><p>Most expensive – only available from specialty pharmacy.</p></td></tr><tr><td><p><strong>Prednisolone</strong></p></td><td><p>Least expensive</p><p>Oral administration</p></td><td><p>Adverse effects: Immune suppressant, edema, gastric bleeding, weight gain, irritability, sleep disturbance, HTN, cortical atrophy, HPA axis suppression, death.</p><p>Potentially less effective vs. ACTH.</p></td></tr><tr><td><p><strong>Vigabatrin</strong></p></td><td><p>Most effective option for patients with TSC (treatment of choice)</p><p>Oral administration</p></td><td><p>Adverse effects: 15 to 30% sedation, behavioral changes, sleep disturbance, weight gain, psychosis, 25-50% irreversible peripheral vision loss (time and dose dependent), reversible MRI changes.</p><p>Expensive and REMS program enrollment required.</p><p>Less effective vs. ACTH (exception: patients with TSC)</p></td></tr></tbody></table></div><p><strong>Response to treatment:          Knupp et al Ann Neurol 2016; Lux et al UKISS trial Lancet 2005)</strong></p><ul><li>Standard first-line medications (ACTH, prednisolone, vigabatrin):  46% response rate overall; higher for steroids</li><li>Second-line medications (Topamax, Zonegran, valproate):  9% response rate  </li><li>Etiology and development do NOT influence response patterns (exception:  vigabatrin is superior for TSC).&nbsp;</li></ul><p><strong>High Dose Steroids: </strong></p><p><strong>ACTH or prednisolone        .NRESISACTH     .NRESISPREDNISOLONE</strong></p><p>1.     Prednisolone is available from regular pharmacies.  However, Adrenocorticotropin Hormone (also called ACTH, Corticotropin, or Acthar Gel) for home use is only available from specialty pharmacies.   Complete ACTH paperwork expediently, recognizing that paperwork is usually not processed on weekends.</p><ul><li>Please notify Inpatient RN Case Manager ASAP and provide the Acthar Referral/Prescription Form (found on the ACTHAR.com website (contact pharmacy for current form)) <strong>with the following sections completed:</strong><ol><li>HCP Information (section 3) – the attending neurologist is the HCP</li><li>Prescription: H.P. ACTHAR Gel (section 4)</li><li>Prescription Consent &amp; Statement of Medical Necessity (section 5)</li><li>Diagnosis &amp; Medical Information (section 6) – a brief summary or recent note is sufficient</li><li>Relevant Treatment History and history of Corticosteroid Use (section 7)</li><li>HCP Signature</li></ol></li><li>RN Case Manager will complete other sections, fax information, contact ACTHAR, and follow up with the ACTHAR and update teams and parents.</li></ul><p>2.     <strong><em>Pre-treatment Screening:</em></strong>  Screen for pre-existing illness or tuberculosis (TB) exposure</p><ul><li>Evaluation for infectious etiology (e.g., CBC and UA) is only necessary if clinically indicated.  Routine workup is not needed for an otherwise healthy appearing child.  Hold initiation of high dose steroids if there is clinical suspicion for infection. </li><li>For patients considered at high risk of TB (history of travel or potential exposure), place PPD skin test and confirm negative results before administering steroids.  If PPD is positive, obtain chest X-ray and Infectious Disease consult, and hold steroids until cleared by Infectious Disease.  Note: PPD is preferable to Quantiferon-Gold (IGRA) because the IGRA blood test may not be accurate in children less than 2y old.</li></ul><p>0.     <strong><em>ACTH Dosing (Infants and children &lt; 2 years)</em></strong>: There is no clear consensus in the literature as to whether the high dose or low dose ACTH treatment protocol is best. High dose ACTH is felt to possibly be more effective, but with higher side effects. High dose ACTH (75 units/m<sup>2</sup>/dose twice a day, with the following tapering schedule) is currently the recommended dosing on the package insert (i.e. FDA-approved dosing regimen).</p><p><strong>Table: High dose ACTH Protocol:</strong> dosing based on body surface area (requires weight and height).  Attending and at least one other person should verify ACTH dosing using resources such as Excel calculator, Acthar app, and inpatient orders. **See dosing spreadsheet “ACTH Calculation Spreadsheet” on Epilepsy page on Intranet for dosing calculation calculation**</p><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Schedule</strong></p></td><td><p><strong>Dosing – via intramuscular injection</strong></p></td></tr><tr><td><p>Day 1-14 (weeks 1 and 2)</p></td><td><p>75 Units/m<sup>2</sup> /dose twice a day</p><p>Note – it is acceptable for the patient to receive only one dose on Day 1</p></td></tr><tr><td><p><strong>Taper over two weeks (weeks 3 and 4):</strong></p></td><td></td></tr><tr><td><p>Day 15-17</p></td><td><p>30 Units/m<sup>2</sup> /dose every morning</p></td></tr><tr><td><p>Day 18-20</p></td><td><p>15 Units/m<sup>2</sup> /dose every morning</p></td></tr><tr><td><p>Day 21-23</p></td><td><p>10 Units/m<sup>2</sup> /dose every morning</p></td></tr><tr><td><p>Day 24-30</p></td><td><p>10 Units/m<sup>2</sup> /dose every other morning (Days 25, 27, and 29).  On Day 30, treatment is complete.</p></td></tr></tbody></table></div><ul><li><strong><em>Prednisolone Dosing</em></strong>:  Prednisolone is the active metabolite of prednisone and may have better bioavailability. There is no clear consensus in the literature as to whether high dose (4 mg/kg/DAY; Lux et al UKISS trial; Kossoff et al Epilepsy Behav 2009) or very high dose (8 mg/kg/DAY; UCLA study Hussain et al Epilepsia 2014) prednisolone protocol is best.  Very high dose prednisolone may be more effective, but possibly with higher side effects.  The recommended approach is the very high dose prednisolone protocol (8mg/kg/DAY or ~2.6mg/kg/dose three times a day).</li></ul><p><strong>Table: Oral Prednisolone Protocol – Schedule and Dosing (Attending must verify dosing)</strong></p><div class=\"table-wrap\"><table><tbody><tr><td><p>Days </p></td><td><p>Dose – prednisolone 15 mg/5 mL suspension</p></td></tr><tr><td><p>1-14</p></td><td><p>2.6mg/kg/dose three times a day (~8mg/kg/DAY).  Max 60 mg/DAY</p><p>(see next table for convenient oral dosing by weight)</p></td></tr><tr><td><p>15-21</p></td><td><p>2.6mg/kg/dose twice a day</p></td></tr><tr><td><p>21-28</p></td><td><p>2.6mg/kg/dose once a day </p></td></tr><tr><td><p>29</p></td><td><p>stop prednisolone</p></td></tr></tbody></table></div><img src=\"/images/epilepsy/img-24.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><p>e.g.  5 kg baby would receive 12 mg (4 mL) three times a day x 2 weeks.  To taper, give 12 mg (4 mL) twice a day x 1 week, then 12 mg (4 mL) daily x 1 week, then stop.</p><p><strong>Dosing</strong></p><div class=\"table-wrap\"><table><thead><tr><th><p><strong>Weight (kg)*</strong></p></th><th></th><th><p><strong>mg per dose</strong></p></th><th><p><strong>mL per dose</strong></p></th></tr></thead><tbody><tr><td><p>≤3.3</p></td><td><p>7.5 mg</p></td><td></td><td><p>2.5 mL</p></td></tr><tr><td><p>3.4-3.9</p></td><td><p>9 mg</p></td><td></td><td><p>3 mL</p></td></tr><tr><td><p>4-4.4 </p></td><td><p>10.5 mg</p></td><td></td><td><p>3.5 mL</p></td></tr><tr><td><p>4.5-5</p></td><td><p>12 mg</p></td><td></td><td><p>4 mL</p></td></tr><tr><td><p>5.1-5.5</p></td><td><p>13.5 mg</p></td><td></td><td><p>4.5 mL</p></td></tr><tr><td><p>5.6-6.1</p></td><td><p>15 mg</p></td><td></td><td><p>5 mL</p></td></tr><tr><td><p>6.2-6.7</p></td><td><p>16.5 mg</p></td><td></td><td><p>5.5 mL</p></td></tr><tr><td><p>6.8-7.4</p></td><td><p>18 mg</p></td><td></td><td><p>6 mL</p></td></tr><tr><td><p>≥7.5</p></td><td><p>19.8 mg</p></td><td></td><td><p>6.6 mL</p></td></tr><tr><td><p>*round up to nearest 0.1 kg</p></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr></tbody></table></div><p><strong>Treatment failure:</strong></p><p>If ACTH or prednisolone treatment has failed after 2 weeks (see “Follow-up for all therapies” section), consider switching to an alternative agent with a different mechanism of action (i.e. vigabatrin).  Taper the steroids using the protocol above, while simultaneously beginning an alternative agent.  If an expedited taper is necessary, discuss dosing with endocrine.</p><p>1.     <strong><em>Gastrointestinal prophylaxis</em></strong>: H<sub>2</sub> blocker or proton pump inhibitor <strong>x 4 weeks.</strong></p><p>2.     <strong><em>Pneumocystis jirovecii</em> pneumonia (PJP) prophylaxis</strong> with Bactrim 2.5 mg/kg/dose BID on three consecutive days each week (preferred practice is Mon, Tues, and Wed) <strong>x 8 weeks.</strong></p><p>3.     <strong><em>Immunizations</em></strong>: Consult the Red Book for latest recommendations.  <strong>In general, LIVE-virus vaccines should be deferred until 4 weeks after discontinuation of steroids.</strong>  Inactivated vaccines can be given during corticosteroid treatment if caregiver adherence with follow-up is not likely.</p><p>4.     <strong><em>Stress dose steroids</em></strong>: During taper of steroids and afterwards for a period of time equal to the full treatment course, patients will have adrenal insufficiency (e.g. a patient treated with 4 weeks of ACTH will have adrenal insufficiency for 4 weeks following cessation of therapy). With any signs of illness (fever, vomiting, diarrhea, hospitalization, or trauma), the patient should be evaluated for hypoglycemia and hypotension and may need stress dose steroids.  Consult Endo with questions.</p><p>5.     <strong><em>Monitoring</em></strong>: Common side effects from steroids include hypertension, hyperglycemia, irritability, immunosuppression, stomach irritation, increased appetite, and adrenal crisis (especially if stopped abruptly).</p><p>6.     Hypertension (HTN): </p><ul><li>Blood pressure monitoring is required 2-3 times per week, typically by the PCP but can be arranged via Neurology RN office visits.  Ensure that appropriate size BP cuff is available.</li><li>Sustained HTN is defined as systolic blood pressure (SBP) greater than 95<sup>th</sup>% (SBP 102) for 3 consecutive days. </li><li>Sustained HTN can be a sign of steroid-induced endocrine dysfunction or cardiomyopathy (septal hypertrophy), which can develop within 5 days of starting ACTH treatment.  HTN should be monitored closely and treated promptly, following the full <strong>HTN algorithm in the Infantile Spasms clinical pathway</strong>, summarized briefly here:<ol><li>Obtain BMP.  If abnormal, consider diuretic and Endo consult.  If normal, consider propranolol and Nephro consult.</li><li>Obtain echocardiogram. If abnormal, consult Cardiology urgently.  Work-up should include<strong> BMP</strong> (ACTH or prednisolone) and <strong>echo</strong> (ACTH).  Anti-hypertensive medication choice depends on these results; see treatment algorithm on next page. </li><li>We no longer recommend weaning the steroids early, because weaning does not improve hypertension immediately and may result in relapse of infantile spasms.</li></ol></li><li>Hyperglycemia:<ol><li>Weekly glucose monitoring is required, with blood glucose or urine glucose dipsticks. </li><li>Educate family to notify PCP of increased urine output. </li><li>If hyperglycemia occurs (glucose &gt;200), obtain BMP to check for hypokalemia. Insulin treatment may be required.  Page Endocrinology 303 201-0927 for treatment plan.</li></ol></li></ul><ul><li><strong>Patients treated with steroids for IS require coordinated care, typically arranged as follows:</strong></li></ul><p>TEAM RESPONSIBILITIES:</p><ul><li>Order/schedule brain MRI without contrast (unless previously performed). </li><li>Screen for signs and symptoms of infection and only if present, order infectious work-up.</li><li>Assess for TB risk factors and only if present, place PPD. Quant gold is not sufficient for children under 2 years.  Do not start steroids until PPD is negative at 48h.  If PPD is positive, consult ID.</li><li>Obtain baseline BMP, Vit D, and blood glucose prior to steroid initiation.</li><li>Check blood pressure and weight at least daily while inpatient.</li><li>Order GI prophylaxis and provide outpatient prescription for <strong>one</strong>-month supply.  Round the dose to a convenient volume.</li><li>Order PJP prophylaxis with Bactrim 2.5 mg/kg BID every Mon/Tues/Wed and provide outpatient prescription for a <strong>two</strong>-month supply.  This can be started on the first Mon after treatment initiation.  Round the dose to a convenient volume.</li><li>Ask bedside RN to print and review with the family the patient handouts regarding infantile spasms and ACTH (available on intranet) and write-in the specific dosing of the medications according to the dosing chart in the Neurology note.   Explain weaning schedule carefully.</li></ul><p><strong>Neurology responsibilities</strong></p><p>·       Discuss treatment options in detail with patient's family, including pros and cons.</p><p>·       For ACTH: complete Acthar paperwork, give it to case management to fax, and verify with case management that it has been received. Note:  Kaiser insurance requires a different process.</p><p>·       Confirm that the cortisol deficiency FYI is added to the patient's Epic chart (regarding risk of adrenal crisis/insufficiency while on high dose steroids and for 2 months afterwards).</p><p>OUTPATIENT PLANNING:    </p><p><strong>Pediatric Team Responsibilities:</strong></p><p>·       Ensure that ACTH or prednisolone dosing schedule is listed on the AVS and outpatient MAR.</p><p>·       Shred the written prescriptions for ACTH.  Provide the caregivers the prednisolone prescriptions.</p><p>·       Arrange PCP visits 2-3 times a week while on steroids for BP and glucose checks.</p><p>·       Provide PCP with info about caring for patients treated with ACTH/prednisolone, such as avoiding live vaccines during treatment and for up to 4 weeks after treatment cessation. </p><p>·       Order extended outpatient EEG to be completed 12-16 days after starting treatment (this order is part of the Infantile Spasms EPIC Orderset).</p><p><strong>Neurology Team Responsibilities</strong></p><p>·       Provide family an Emergency Letter regarding risk of adrenal crisis/insufficiency.  </p><p>·       Arrange outpatient neurology follow-up with EEG approximately 2 weeks after starting treatment.</p><ul><li>Algorithm for sick child considerations with use of steroids within the past 4 weeks:</li></ul><p><strong>Vigadrone/Vigabatrin (Sabril)       </strong></p><p>REGARDLESS OF WHICH FORMULATION OF VIGABATRIN IS CHOSEN, THE FOLLOWING MUST BE COMPLETED FOR ALL PATIENTS PRIOR TO PRESCRIBING</p><ul><li>    Give and review “What You Need to Know About Vigabatrin Treatment: A Patient Guide” with families.  This can be found the REMS program website (contact pharmacy for current materials).</li><li>    Fill out the Parent/Physician agreement form (contact REMS program for current form).  This is completed on paper, signed by parent/guardian and provider and faxed in to the vigabatrin REMS program. Alternatively, this can be completed online when the family is in clinic if you are REMS certified. However, when prompted if the family is in the room with you, select “NO” to proceed.</li></ul><p><strong>&nbsp;</strong>VIGABATRIN OPTIONS</p><div class=\"table-wrap\"><table><tbody><tr><td><p>Drug Manufacturer</p></td><td><p>Drug Name</p></td><td><p>Formulation</p></td><td><p>Patient Support Program</p></td><td><p>Prescription Forms</p></td><td><p>Fax # for submission</p></td><td><p>Specialty Pharmacies</p></td></tr><tr><td><p>Lundbeck</p></td><td><p>Sabril</p></td><td><p>500mg sachets to mix for oral solution</p><p>500mg scored tablet</p></td><td><p>Share<em>Plus</em> – <strong>For commercially insured patients only</strong>:</p><p>·  Benefits investigation</p><p>·  PA Support</p><p>·  Provide 30-day starter supply as PA is processed</p><p>·  Co-pay assistance</p></td><td><p>Found online at sabril.net or <a href=\"https://www.sabril.net/content/dam/lundbeck/active/neurology/sabril/pdf/sabril-prescription-form.pdf\">here</a>.</p><p>Must sign DAW if name brand is requested and to access SharePlus program.</p></td><td><p>1-877-742-1002</p><p>Will NOT ship on weekends.</p></td><td><p>Accredo, Walgreens, CVS Caremark</p></td></tr><tr><td><p>Par Pharmaceuticals</p></td><td><p>vigabatrin</p></td><td><p>500mg sachets to mix for oral solution</p></td><td><p>No fancy name -</p><p><strong>For commercially insured patients only:</strong></p><p>·  Benefit investigation</p><p>·  If PA is required, will send out 10 day started supply (x2)</p><p>·  Co-pay assistance up to $75/month (no limit)</p><p>·  Free drug if no insurance or insurance denies coverage</p></td><td><p>Call 833-727-4357 for most updated prescription forms.</p><p>Their forms are not available online.  You must use their form and cannot send a script alone.</p></td><td><p>1-844-823-9356</p></td><td><p>Accredo, Walgreens, CVS Caremark</p></td></tr><tr><td><p>Upshire-Smith</p></td><td><p>Vigadrone</p></td><td><p>500mg sachets to mix for oral solution</p></td><td><p>Access Pathways – <strong>for all patients regardless of payor</strong>:</p><p>·  Benefits investigation</p><p>·  PA Support</p><p>·  Provide 7-day starter and up to 3 bridge supplies if needed.</p><p>·  Cash option for no coverage or underinsured</p><p>·  Co-pay assistance for commercially ensured.</p></td><td><p>Found online at vigadrone.com or <a href=\"https://vigadrone.com/wp-content/uploads/2018/06/113034.02-VIG-Prescription-Form-DIGITAL.pdf\">here</a>.</p><p>Form can be filled out online and then printed for signature.</p><p>Parents can be consented via phone with two witnesses signing</p></td><td><p>1-877-788-4948 (M-F 8am-9pm EST)</p><p>1-877-788-4942 (Fri 9pm-Sun 9pm)</p><p>Will ship on weekends.</p></td><td><p>Accredo, Walgreens, CVS Caremark, PatheRx</p></td></tr></tbody></table></div><p>3.    Complete appropriate manufacturer’s prescription forms based on your selection above.</p><p>4.    Provide REMS Parent/Physician Agreement and all prescription forms to either the clinic MA (if starting outpatient) or the inpatient Case Manager (if starting inpatient).  They will be responsible for faxing all forms and following-up on their receipt.  All phone numbers are included on each respective form.</p><p>5.    Also note, when ordering inpatient, the pharmacy dispenses a 7-day supply which is based on the Day 1 dose, so consider adjusting the schedule to ensure that this supply will actually be sufficient for 7 days. </p><p>6.    Dosing: 50mg/kg/day divided BID x3days, 100 mg/kg/day divided BID x3days, then 150mg/kg/day divided BID thereafter.  </p><p>7.    Additional titration steps can be added for patients at risk for side effects (ie a child already having issues with somnolence), such as 25 mg/kg/DOSE BID x3days, 40 mg/kg/DOSE BID x 3days, 60 mg/kg/dose BID x 3 days, then 75 mg/kg/DOSE BID thereafter. </p><p>8.    Doses can be rounded to the nearest 25 mg and/or packet size for convenience, ideally staying within 70-80 mg/kg/<strong>DOSE</strong> (140/160 mg/kg/day) for the target maximum dose.</p><p>9.    Obtain baseline ophthalmology screening before or within 4 weeks after starting vigabatrin, and every 3 months during treatment until vigabatrin is stopped. It is also recommended that vision be tested about 3 to 6 months after stopping.</p><p>Weekend, Holiday, and After-Hours Considerations</p><p>Vigabatrin</p><p>REMS number</p><p>·       Faxed REMS forms will only be processed 8 AM – 8 PM EST, Monday-Friday.  They are closed on weekends and holidays.</p><p>Vigadrone prescription form</p><p>·       Case Management is available Monday-Friday, 8 AM – 4 PM to assist with the prior authorization.</p><p>·       Access Pathways support (aka Panther Rx) is available 8 AM – 8 PM EST, Monday-Friday to process prescriptions.</p><p>ACTH</p><p>·       Case Management is available Monday-Friday, 8 AM – 4 PM to assist with the prior authorization.</p><p>·       ACTHAR Support (who processes the prescription form) is available Monday – Friday, 8 AM – 9     PM EST and Saturday, 9 AM – 2 PM EST.  They are closed on Sundays and holidays.</p><h2 id=\"follow-up-for-all-therapies\">Follow-up for all therapies</h2><p>Following the initiation of any first-line treatment, efficacy of therapy should be assessed by <strong>2 weeks</strong>. Short-term outcomes include cessation of spasms and EEG confirmation of resolution of hypsarrhythmia. </p><p>·       EEG should be used to assess for resolution of spasms and hypsarrhythmia at 12-16 days. </p><p>·       Clinic visit with pediatric neurology should occur at the same time frame as repeat EEG.</p><p>·       If spasms or hypsarrhythmia persist at 2 weeks, consider switching treatment to an alternative first-line treatment with a different mechanism of action. Follow the weaning protocols outlined for the specific first-line agent. Efficacy of the alternative therapy should be assessed at 2 weeks.</p><p>·       Consider repeat EEG 1-4 weeks after completion of treatment to confirm sustained efficacy.  Also consider repeat EEG if there is concern for developmental plateau/regression or clinical seizures.</p><p>·       PCP and neurology should monitor neurodevelopment closely and involve Early Intervention services when appropriate.  A diagnosis of IS qualifies for Early Intervention.</p><h1 id=\"febrile-seizures\">Febrile Seizures</h1><p><strong>Definition: </strong> Seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method withing surrounding 24hr period), without intracranial / central nervous system infection, that occurs in infants and children 6 - 60 months of age. </p><p><strong>Epidemiology:</strong>  2-5% of children, 90% within first 3 years</p><p><strong>Simple febrile seizure:</strong> Brief &lt;15 minutes and generalized</p><p><strong>Complex febrile seizure:</strong> Duration &gt;15 minutes OR more than 1 seizure in 24 hours OR focal features; 20-30% of cases</p><p>NB: with re: multiple within 24 hours (evidence suggests outcomes are similar to simple febrile sz - 'simple febrile sz flurry')</p><p><strong>Evaluation</strong></p><p>·      Important to consider that 2-5% of children with meningitis present as an apparent febrile sz</p><p>·      AAP recommends strongly considering LP for unvaccinated children 6-12 months of age</p><p>·      Strongly consider LP in children with complex febrile seizures &lt; 12 months</p><p>·      Head CT only when concern for trauma or increased ICP</p><p>·      EEG is not helpful in simple febrile seizure</p><p>If complex, may consider EEG --&gt; if focal findings, will likely have brain MRI &nbsp;</p><p>- Ideally, EEG when back to baseline (not in post-ictal state)</p><h2 id=\"treatments\">Treatments:</h2><p><strong>Simple febrile seizure: </strong></p><ul><li>Geared towards underlying illness, (common with Roseola, Shigella, Varicella)</li></ul><p>Aggressive antipyretic therapy has not been shown to decrease risk of febrile seizures, as seizure is related to rate of temperature change, and frequently occurs before fever is documented</p><p>Some old efficacy data for ppx ASMs, but risks generally &gt; benefits (Ped. ’99; 103:1307).</p><p>For complex febrile seizures marked by clusters, consider rescue medication</p><ul><li>Does not generally need EEG or imaging</li><li>Still consider LP if c/f meningitis (NB: meningeal signs are difficult to observe in infants/toddlers) </li><li>Generally, do not require rescue med or neurology follow-up -- though can be tailored to situation</li></ul><p><strong>Complex febrile seizure:</strong></p><p>·      Consider rescue med if recurrent seizures, family lives far away, etc; defer to attending</p><p>·      Consider OP EEG, MRI, and neurology follow-up if seizure was focal</p><p>·      Consider LP in children with complex febrile seizures &lt; 12 months</p><h3 id=\"prognosis\"><strong>PROGNOSIS</strong></h3><p><strong>Prognosis after Simple: <br></strong>• Increased risk of recurrent febrile seizures</p><ul><li>~30-33% will have one or more recurrences</li><li> ~10% with 3 or more recurrences</li><li>Most (75%) recurrent febrile seizures occur within 1 year</li></ul><p>• No evidence of increased mortality, hemiplegia, or mental retardation.<br>• Risk of epilepsy shown to be only slightly higher than that of the general population (1 --&gt; 1.7%) </p><p><strong>Risk Factors for First Febrile Seizure:</strong></p><ul><li>Family history of febrile seizures</li><li>Neonatal discharge ≥ 28 days</li><li>Delayed development</li><li>Very high fever</li><li>Child care attendance</li><li>Low serum sodium</li></ul><p><strong>Risk Factors for Recurrence of Febrile Seizure:</strong></p><ul><li>Younger age (&lt;18 months)</li><li>Family history of febrile seizures (1st degree relative)</li><li>Shorter duration of fever before the initial seizure (&lt;1hr)</li><li>Relatively lower fever at the time of initial seizure (&lt;39C)</li><li>Multiple seizures during febrile illness</li><li>Daycare attendance</li><li>Family history of epilepsy</li></ul><p><strong>Risk Factors for the Development of Epilepsy Following Febrile Seizures:</strong></p><ul><li>Suspected or abnormal development before the first seizure</li><li>Family history of afebrile seizures</li><li>Complex first febrile seizure</li></ul><p><strong>What to tell families</strong></p><p>There is no evidence that simple febrile seizures cause any structural damage or cognitive decline</p><p>Rule of 3s, about <strong>3%</strong> of kids have febrile seizures, about <strong>1/3</strong> of those will have recurrent febrile seizures, ½ of those will have a <strong>3<sup>rd</sup></strong>, and the risk of epilepsy is about <strong>3x</strong> greater than general population (but still only <strong>3%</strong>)</p><p>Below is a flow diagram that you may want to consider, please also refer to your attending.</p><p>Complex Febrile Seizures: A Practical Guide to Evaluation and Treatment. Journal of Child Neurology, 2013.</p><p>Good articles for febrile seizures</p><p>Patel and Vidaurre. Complex Febrile Seizures: A Practical Guide to Evaluation and Treatment. Journal of Child Neurology, 2013.</p><p>Febrile Seizures: Clinical Practice Guideline for the Long-term Management of the Child With Simple Febrile Seizures: <em>Pediatrics </em>2008;121:1281–1286</p><p>Shinnar and Glauser. Febrile Seizures:  <em>J Child Neurol </em>2002;17:S44–S52).</p><h1 id=\"first-unprovoked-afebrile-seizure\">First \"Unprovoked\" Afebrile Seizure</h1><p>Practice Parameter: evaluating a First Nonfebrile Seizure in Children. Neurology 2000;55:616-62</p><p><strong>Diagnostics to rule out symptomatic etiologies in the ED:</strong></p><ul><li>Electrolytes if the child is &lt; 6 months old; otherwise not needed if the seizure has stopped and the child looks well, and has no known reason for electrolyte derangement.</li><li>UTOX if prolonged post-ictal state or <em>any</em> suspicion (have a low threshold, strongly consider in adolescents)</li><li>CBC and UA if infection suspected in an infant or child.</li><li>LP: Strongly consider in all infants &lt;6 months  </li></ul><p><strong>Neuroimaging:</strong></p><ul><li>Brain imaging is often not needed for generalized seizures or recognizable self-limited epilepsy syndromes</li><img src=\"/images/epilepsy/img-40.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><li>Imaging is indicated for:<ul><li>Patients of any age with focal findings during or after the seizure</li><li>Focal EEG abnormality (unless the features are consistent with a known epilepsy syndrome)</li><li>Abnormal patient exam such as motor or limb size asymmetry or skin findings associated with brain</li><li>Abnormalities such as neurofibromatosis, tuberous sclerosis, and patches of discolored hair (which can be associated with underlying focal cortical dysplasia)</li><li>Any concern for child abuse or traumatic cause of seizures – in this case, consider CT for evaluation</li></ul></li></ul><p><strong>EEG:</strong></p><ul><li>Outpatient EEG in all patients within 2 weeks.</li><li>If not returning to baseline—consider obtaining to rule out nonconvulsive status</li></ul><p><strong>Management:</strong></p><p>·       Observe in ED for 6 hours after seizure, longer in infants/toddlers (consider admission)</p><p>·       No ASMs</p><p>·       Neurology appt in new onset seizure clinic or any provider</p><p>·       Seizure precautions</p><p>·       Rescue: Diastat/Intranasal Versed</p><p><strong>Recurrence risk</strong></p><ul><li>In a long-term, prospective cohort study in the Bronx, otherwise healthy children with normal interictal EEGs after a single unprovoked seizure had seizure recurrence rates of 28% and 32% at 2 and 5 years, while children with abnormal EEGs had seizure recurrence rates of 52% and 59% at 2 and 5 years.</li></ul><h1 id=\"epilepsy-syndromes\">Epilepsy Syndromes</h1><h2 id=\"2017-seizure-classification\">2017 Seizure Classification</h2><h3 id=\"epilepsy-diagnosis\"><strong>Epilepsy diagnosis:</strong></h3><p>·      At least two unprovoked seizures occurring more than 24 hours apart.</p><p>·      One unprovoked seizure and a probability of further seizures that is similar to the general recurrence risk after two unprovoked seizures (ie  ≥ 60 %)</p><p>·      Diagnosis of an epilepsy syndrome.</p><ul><li>Considered resolved: If seizure-free for 10 years with no seizure medications for 5 years.</li></ul><p><strong>Epilepsydiagnosis.org: Information of seizures types / epilepsy syndromes / video examples</strong></p><h3 id=\"syndromes\"><strong>Syndromes:</strong></h3><p><strong>Epilepsy with Myoclonic-Atonic Seizures (Formerly Myoclonic-Astatic Epilepsy or Doose Syndrome)</strong></p><ul><li>See “Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures/ Doose syndrome” by Joshi et al 2021 for diagnostic criteria</li></ul><p>·       Age of onset: Usually 2-4 years but always within first 5 years of life</p><p>·       Development: normal prior to onset</p><p>·       Seizure types: Myoclonic, atonic/astatic, GTC, NCSE, tonic, absence. Must have myoclonic-atonic seizures.</p><p>·       EEG: Central theta</p><p>·       Treatment: Valproate, clobazam, and rufinamide are frequently used.  Very sensitive to ketogenic diet and felbamate.</p><p>·       Prognosis: “usually burns out,” many left with intellectual delay of some degree.</p><p><strong>Dravet Syndrome (SCN1A, Severe Myoclonic Epilepsy of Infancy)</strong></p><p>o   See “Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel” by Wirrell et al 2017 for diagnostic criteria</p><p>·       Age of onset: Infancy</p><p>·       Development: Poor, especially language and motor skills</p><p>·       Seizure Types: Prolonged febrile convulsions, GTC, Status, myoclonus</p><p>·       Treatment: Typical triad includes Depakote, Clobazam and Stiripentol.  Fenfluramine, Epidiolex also approved specifically for this syndrome. Avoid Na channel blockers.</p><p>·       Prognosis: Poor development</p><p><strong>Lennox-Gastaut Syndrome</strong></p><p>·       Age of onset:  Prior to age 4</p><p>·       Development: Poor</p><p>·       Seizure type: Tonic, atonic, atypical absence, myoclonic</p><p>·       EEG: Slow spike and wave, paroxysmal fast activity</p><p>·       Treatment:  Most ASMs. </p><p>·       Prognosis: Varies, but usually poor</p><p><strong>West Syndrome</strong></p><p>·       Age of onset: Infancy</p><p>·       Seizure type: Epileptic spasms</p><p>·       Triad: Infantile spasms, developmental delay, and hypsarrhythmia.</p><p>·       Treatment: ACTH, prednisolone, vigabatrin, Keto diet. </p><p>·       Prognosis: Poor</p><p><strong>Childhood Absence Epilepsy</strong></p><p>·       Age of onset: 2-12 years, Average 5-6 yr.</p><p>·        *Onset of absence seizures &lt;4yo: Consider glucose transporter disorders</p><p>·       Seizure type: Absence, 10-40% with GTCs</p><p>·       EEG: 3 Hz spike wave generalized discharges</p><p>·       Development: Predisposed to ADHD, behavioral problems</p><p>·       Treatment:  Ethosuximide, valproate, lamotrigine</p><p>·       Prognosis: Resolves in most patients</p><p><strong>Juvenile Absence Epilepsy</strong></p><p>·       Age of onset: Puberty to early adolescence</p><p>·       Seizure type: Absence (less frequent/longer than CAE), 80% have GTCs</p><p>·       EEG: 3-4 Hz spike wave generalized discharges.</p><p>·       Development: Normal</p><p>·       Treatment: Valproate, lamotrigine, +/-ethosuximide.</p><p>·       Prognosis: Med responsive but commonly lifelong</p><p><strong>Juvenile Myoclonic Epilepsy</strong></p><p>·       Age of onset: Puberty and on</p><p>·       Seizure type: Myoclonic, GTCs, sometimes absence</p><p>·       Development: Normal</p><p>·       Treatment: Valproate, lamotrigine, Keppra</p><p>·       Prognosis: Usually med responsive but requires lifelong therapy. 25% achieve long-term seizure freedom off of medication per UpToDate</p><p><strong>Ohtahara Syndrome (Early Infantile Developmental &amp; Epileptic Encephalopathy)</strong></p><p>·       Age of onset: Early infancy (first 3 months)</p><p>·       Seizure type: Epileptic spasms, focal seizures</p><p>·       EEG: “Suppression-burst” pattern</p><p>·       Development:  Poor</p><p>·       Treatment: ACTH, vigabatrin, clobazam, zonisamide, surgery</p><p>·       Prognosis: Very poor.  High mortality, severe impairment</p><p><strong>Self-Limited Childhood Epilepsy with Centrotemporal Spikes (SeLECTS)</strong></p><p>·       Age of onset: 3-14yo (peak 8-9yo)</p><p>·       Seizure type: Focal onset convulsions (orofacial), may progress to bilateral tonic-clonic</p><p>·       EEG: bilateral centrotemporal spikes with a horizontal dipole on a normal background</p><p>·       Development: Normal</p><p>·       Treatment: Not necessary unless freq. seizures or daytime seizures.  Oxcarbazepine and carbamazepine.</p><p>·       Prognosis: Excellent.  Resolves in nearly all patients, usually by 13yo but may be later</p><h1 id=\"epilepsy-and-driving\">Epilepsy and Driving</h1><p>·      If child has genetic generalized epilepsy or history of absence seizures (ie JAE, JME), most would obtain 24 hour EMU study to evaluate for subtle clinical seizures</p><p>·      If noted to have discharges lasting 3 seconds or longer (or shorter with clinical correlate) most would not recommend driving</p><p>·      Consensus: should be 6 months seizure-free without changes to anti seizure medications prior to driving</p><p>·      Counseling recommendation:</p><p>o   If you miss even a single dose of medication, no driving for 2-3 days</p><p>o   If you don’t get a good night’s sleep, no driving for 1-2 days</p><p>o   If any concern for seizure, stop driving immediately and call and you must be re-cleared to drive</p><p>Australian driving decision tree, for reference: Somerville et al, A decision tree to determine fitness to drive in epilepsy: Results of a pilot in two Australian studies. Epilepsia, 60(7): 2019.</p><h1 id=\"seizure-semiology\">Seizure Semiology</h1><p><strong>Seizures  </strong>Seizures result from abnormal excessive rhythmic neurologic electrical activity. This abnormal activity can occur in both hemispheres (generalized seizure) or within one hemisphere (focal seizure), which may spread to the entire brain. <strong>Generalized tonic-clonic seizures </strong>– motions of which consist of a tonic phase with muscle stiffening, followed by a clonic phase with rhythmic muscle contractions. <strong>Focal seizures more often occur in the setting of cerebral insult.</strong> Unlike generalized seizures, symptoms of focal seizures vary according to the anatomic location of the abnormal electrical activity. Focal seizures can generalize secondarily, known as focal to bilateral tonic clinic seizures (FTBCS; assuming have a tonic-clonic motoric phase).</p><p>Seizures can be motor or non-motor. Non-motor seniologies include behavioral arrest, staring, autonomic signs (pupillary dilation, flushing, retching/rising sensation, emotional symptoms).</p><p>Seizures can subclassified as having impaired awareness or without impaired awareness.</p><p>Seizures can be classified as <strong>provoked or unprovoked</strong>. Provoked seizures are those with <strong>identifiable causes, </strong>which can be isolated to the brain, or are thought to occur secondary to a systemic disorder or illness. Such causes include: brain trauma, CNS infection (i.e. meningitis, encephalitis, brain abscess), anoxic brain injury, intracranial hemorrhage or surgery, metabolic disorders, illicit drug abuse or intoxication (most commonly tricyclic antidepressants and isoniazid), or alcohol withdrawal.&nbsp;Seizures may also occur in the setting of metabolic derangements (hypoglycemia or hyponatremia).</p><p>&nbsp;<strong>Unprovoked seizures</strong> are those with no discernible cause, or those occurring <strong>greater than seven days</strong> following precipitating factors or events. </p><img src=\"/images/epilepsy/img-25.gif\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-26.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-27.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-28.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-29.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-30.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-32.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-31.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><h1 id=\"electroclincal-syndromes-by-age\">Electroclincal Syndromes (by Age)</h1><p><strong>Electroclinical syndromes arranged by age at onset </strong><em>(revised ILAE Classifcation. Epilepsia, 51(4):676–685, 2010) </em></p><p>Neonatal period </p><p>Benign familial neonatal epilepsy (BFNE) </p><p>Early myoclonic encephalopathy (EME) </p><p>Ohtahara syndrome </p><p>Infancy</p><p>Epilepsy of infancy with migrating focal seizures</p><p>West syndrome</p><p>Myoclonic epilepsy in infancy (MEI)</p><p>Benign infantile epilepsy</p><p>Benign familial infantile epilepsy</p><p>Dravet syndrome</p><p>Myoclonic encephalopathy in nonprogressive disorders </p><p>Childhood</p><p>Febrile seizures plus (FS+) (can start in infancy)</p><p>Panayiotopoulos syndrome</p><p>Epilepsy with myoclonic atonic (previously astatic) seizures</p><p>Benign epilepsy with centrotemporal spikes (BECTS)</p><p>Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE)</p><p>Late onset childhood occipital epilepsy (Gastaut type)</p><p>Epilepsy with myoclonic absences</p><p>Lennox-Gastaut syndrome</p><p>Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS) </p><p>Landau-Kleffner syndrome (LKS)</p><p>Childhood absence epilepsy (CAE) </p><p>Adolescence – Adult</p><p>Juvenile absence epilepsy (JAE) </p><p>Juvenile myoclonic epilepsy (JME)</p><p>Epilepsy with generalized tonic–clonic seizures alone </p><p>Progressive myoclonus epilepsies (PME)</p><p>Autosomal dominant epilepsy with auditory features (ADEAF) </p><p>Other familial temporal lobe epilepsies </p><p>Less specific age relationship</p><p>Familial focal epilepsy with variable foci (childhood to adult)</p><p>Reflex epilepsies </p><p>Distinctive constellations</p><p>Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS)</p><p>Rasmussen syndrome</p><p>Gelastic seizures with hypothalamic hamartoma</p><p>Hemiconvulsion–hemiplegia–epilepsy</p><p>Epilepsies that do not fit into any of these diagnostic categories can be distinguished first on the basis of the presence or absence of a known structural or metabolic condition (presumed cause) and then on the basis of the primary mode of seizure onset (generalized vs. focal) </p><p>Epilepsies attributed to and organized by structural-metabolic causes</p><p>Malformations of cortical development (hemimegalencephaly,heterotopias, etc.) Neurocutaneous syndromes (tuberous sclerosis complex, Sturge-Weber, etc.) Tumor</p><p>Infection</p><p>Trauma</p><p>Angioma</p><p>Perinatal insults</p><p>Stroke </p><p>Epilepsies of unknown cause</p><p>Conditions with epileptic sz that are traditionally not diagnosed as a form of epilepsy per se </p><p>Benign neonatal seizures (BNS) </p><p>Febrile seizures (FS) </p><h1 id=\"rite-review\">Rite Review</h1><p><strong>Hypothalamus:</strong></p><p>Anterior: cooling, circadian rhythm (suprachiasmatic nuc) --&gt; * hyperthermia, insomnia</p><p>Posterior: heat conservation --&gt; * hypothermia, poikothermia</p><p>Postero-lateral: arousal (histaminergic) --&gt; *hypersomnia, narcolepsy</p><p>Lateral: increases appetite --&gt; *anorexia</p><p>Medial: Decreases appetite --&gt; *obesity</p><p><strong>Hippocampus:</strong></p><ul><li>Major input: alveolar pathway (from enorhinal cortex --&gt; CA1, CA3 cells)</li><li>Major Output: <ul><li>Perforant pathway (from subiculum --&gt; dentate gyrus/granular cell layer), </li><li>Mossy fibers (from dentate gyrus --&gt; CA3 pyramidal cells ----&gt; Fornix)</li><li>Schaffer collaterals (crom CA3 pyramidal cells --&gt; CA1 cells ----&gt; Fornix).</li></ul></li></ul><p><strong>Amygdala:</strong></p><ul><li>Stria Terminalis: major output tract (travels along wall of lateral ventricles) from amygdala to septal nuclei &amp; anterior hypothalamus</li><li>Stria Medullaris: output tract from the septal nuclei (travels along 3rd ventricle &amp; medical surface of thalamys) to the habenula/epithalamus ----&gt; brainstem/midbrain</li><li>(Ventral) amygdalofugal fibers</li></ul><p>Clinical Epilepsy - Adults:</p><ul><li>Geschwind Syndrome:<ul><li>Personality syndrome seen in epilepsy pts</li><li>Excessive verbal output, hypergraphia, hyposexuality, hyperreligiosity, \"stickiness\"</li></ul></li><img src=\"/images/epilepsy/img-39.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><img src=\"/images/epilepsy/img-38.png\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"><li>Psychiatric behavior that increases risk of Wellbutrin-associates seizures:<ul><li>Bulimia, anorexia</li></ul></li><li>Psych condition most common in epilepsy: depression (50%) --&gt; increased suicide</li><li>Forced normalization:<ul><li>Acute psychosis + EEG is improved</li></ul></li><li>SUDEP Risk factors:<ul><li>Uncontrolled GTC seizures</li><li>Noncompliance</li><li>Multiple AED use (3+), esp carbamazepine</li></ul></li><li>First test to perform on new SE pt: glucose level</li><li>Mesial Temporal Sclerosis: complex partial seizures, secondarily generalized<ul><li>Abnormal smell, masticatory movement, automatisms, confusion (left hmisphere)</li></ul></li><li>Auto-dominant nocturnal frontal lobe epilepsy<ul><li>Brief nocturnal episodes, mistaken for psychogenic events</li><li>Sudden arousal, hyperkinetic (thrashing, screaming, bicycling), automatism, aura of fear</li><li>Minimal postictal symptoms</li><li>Family History +</li><li>Nicotine Ach rec gee mutation</li></ul></li><li>Most Common Cause of SE in elderly pts: stroke (60%)</li><li>AED ppx for new brain tumor:<ul><li>NOT effective in preventing first seizure</li><li>Increased risk of AED side effects</li><li>NOT recommended as long-term ppx</li><li>(should taper off after one week post-op period)</li></ul></li><li>Management after single unprovoked GTC<ul><li>If normal neuro exam; likely idiopathic</li><li>--&gt; 30% recurrence (low) over the next 5 years, so observe WITHOUT starting AED</li></ul></li><li>Risk Factors for recurrent seizures<ul><li>Abnormal neuro exam</li><li>Seizure outside of sleep</li><li>Remote symptomatic etiology</li></ul></li><li>Catamenial Epilepsy<ul><li>Due to increase in pre-ovulatory estrogen increase (decreases GABA, increases NMDR rec), with relative decrease in protective progesterone (increase GABA, decreases glutamate). </li><li>Avoid Valproate acid/AED polytherapy, esp during 1st trimester is possible</li><li>Baby at risk for cognitive defects, which can show up later if not initially obvious</li></ul></li><li>Seizures for several years + nonenhancing superficial cortical mass found on MRI: angiocentric glioma</li><li>Heterotopia causing seizures:<ul><li>Neuronal migration disorder</li><li>Periventricular nodular/Subependymal heterotopias:<ul><li>FLNa gene mutation (filamin1 protein abnormality in girls)</li><li>Abnormally located cluster of neurons/grey matter tissue around ventricles, but normal morphology</li></ul></li></ul></li><li>Subcortical band heterotopias: \"Double cortex syndromes\"<ul><li>DCX/X-Lis fene mutation, X-linked dominant, --&gt; doublecortin protein abnormality in girls (due to moaicism)</li><li>MRI: cortical grey matter ribboning seen within subcortical WM</li><li>***Boys with DCX/Lis1 mutation (Chrom 17) get leissenchephaly</li></ul></li></ul><ul><li>Focal Cortical Dysplaysia causing seizures:<ul><li>Disorder of cortical development due to abnormal neuronal cell proliferation</li><li>Can occur in isolation, or with TSC</li><li>Balloon cells (abnormal cells within germinal matrix)</li></ul></li><li>Next step after patient fails 2nd AED trial?<ul><li>3rd AED ith different mech, combination AED therapy, VNS, KD (better than tryin 3rd AED!), referral for EMU/surgical w/u</li></ul></li><li>\"Sign of ongoing nonconvulsive seizures in a patient intubated and sedated for SE?\"<ul><li>Hypotension, hypertension, pupil dilation, poikilothermia, hypoventilation, elevated CK</li></ul></li></ul><p>CLINICAL EPILEPSY - PEDIARICS</p><ul><li>Benign familial neonatal epilepsy<ul><li>AD VGKC/KCNQ2 or 3 mutations, high penetrance --&gt; diagnosis based on FH+</li><li>Multifocal clonic seizures occurring 203 days after birth</li><li>14% can have recurrent seizures later in life</li><li>EEG nonspecific</li></ul></li><li>Benign Idiopathic neonatal convulsions (non-familial)<ul><li>\"5th day fits\" -- newborns having brief &lt;1min GTC within 1 week of birth</li><li>Apnea, cyanosis, stiffening described</li><li>Good prognosis! Little risk of later epilepsy</li></ul></li><li>Infantile Spasms:<ul><li>West Syndrome - TRIAD: IS + neurodevelopemental delay, hypsarrhythmia</li><li>Infants 3-5mo, usually stops by 4yo (but may progress to LGS)</li><li>Sudden jerk upon awakenin, followed by stiffening 1-2 sec, often in clusters</li><li>\"jack-knife\" seizures --arms fling out, knees draw u, body bends forward</li><li>Associated with underlying brain injury, microcephaly, TSC</li><li>EEG: hypsarrhythmia (sleep), resolves by 2yo</li><li>-- typically followed by slow (2hz_ gen spike-and-wave (LGS)</li><li>Tx: ACTH (TN), vigabatrin (risk of visual defects, use only 6 mo), pred</li></ul></li><li>LGS: <ul><li>Triad: multiple Sz typs, MR, slow-spike and wave EEG pattern</li><li>Refractory to AEDs</li><li>EEG: slow spike and wave</li></ul></li><li>JME<ul><li>MC idiopathic generalized epilepsy seen in young adolescents/teenagers</li><li>Morning myoclonic jerks and GTCs, triggered by sleep deprivation</li><li>EEG: fast (4-6 hz) gen spike and wave</li><li>25% can have photoparoxysmal response</li><li>Tx: VPA, LTG, LVT</li></ul></li><li>Childhood Absence Epilepsy \"Pyknolepsy\" (small seizures)<ul><li>Tx: ethosuximide</li><li>Worsened by: CBZ</li><li>EEG: 3Hz gen spike and wave</li><li>Can trigger via hyperventilation</li></ul></li><li>Otahara Syndrome<ul><li>EIEE/Early infantile epileptic encephalopathy</li><li>1st 3 months</li><li>Tonic Spasms, partial szs, severe MR</li><li>Lesional epilepsy - abnl MRI, cerebral malformations, severe bilateral atrophy</li><li>EEG: bust suppression</li><li>Poor prognosis, often progresses to West Syndrome/LGS</li></ul></li><li>Landaue Kleffner<ul><li>Acquired auditory verbal agnosia, in developmentally normal children</li><li>Progressive decline in language skills, receptive aphasia affected</li><li>Paroxysmal EEG changes in sleep</li><li>EEG: diffuse/focal/temporal spike-wave</li><li>Good prognosis, remits spontaneously in teens</li></ul></li><li>Panayiotopoulous Syndrome<ul><li>Normally developed children, 4-5 yo at onset</li><li>Onset often out of sleep, autonomic sxs, flaccid unresponsiveness, progress to hemiconvulsion (pallor, N/V, flushing, mydriasis, incontinence)</li><li>Focal nonlesional epilepsy (normal MRI)</li><li>Good prognosis, remission usually within a few years (no tx necessary)</li><li>Risk of crdiorespirartory arrest! -&gt; get EKG/ECHO</li></ul></li></ul><h1 id=\"eeg-tips\">EEG Tips</h1><p>Template:</p><p>Patient Name:    DOB:</p><p>Conditions</p><p># of EEG channels: EKG channel: y/n # of Eye channels:</p><p>LFF: HEF: Notch: Sensitivity: Timebase:</p><p>State: awake/drowsy/sleep</p><p>Posterior Rhythm (Hz):</p><p>Symmetry:</p><p>Organization:</p><p>Activations:</p><p>Hyperventilation: present/not present? symmetric/asymmetric?</p><p>(was there \"build up\" or slowing and increase in amplitude with high quality HV?)</p><p>Photic stimulation:</p><p>(at what frequencies did the posterior rhythm appear to track with the photic stim</p><p>rate? Was there photic response after 20 hz?)</p><p>Sleep: present/not present? Architecture normal/not normal?</p><p>N1 slow rolling eye mvmts, EMG starts to drop out, attenuates</p><p>N2: sleep spindles and complexes</p><p>N3+ (rare to see in routine EEG) large amplitude delta slowing</p><p>Focal slowing:</p><p>(any areas of consistently slower wave forms, regardless of the morphology or</p><p>sharpness?)</p><p>Epileptiform Abnormalities:</p><p>Morphology: spike discharge duration 20-70 ms; sharp wave duration 70-200 m;</p><p>spike-and-slow-wave complex classically has aftergoing slow component larger</p><p>than apike; multiple spike-and-slow-wave complex have a run of 2 or more</p><p>complexes</p><p>2. Location: phase reversal with appropriate field spread? Generalized? Bifrontal</p><p>with asymmetry?</p><p>3. Quantity: isolated example/rare/frequent/abundant?</p><p>6. Seizure: Localization and spread pattern</p><p>EKG:</p><p>(especially in sz versus syncope questions, it's important to watch this channel)</p><p>CONCLUSION:</p><p>1. Normal routine length EEG with wake/drowsy/sleep</p><p>2. Abnormal routine length EEG concerning for the following features:</p><p>Frequency:</p><ul><li>Alpha waves - 8-13 Hz</li><li>Beta waves - Greater than 13 Hz</li><li>Theta waves - 3.5-7.5 Hz</li><li>Delta waves - 3 Hz or less</li></ul><h2 id=\"alpha-waves\">Alpha waves</h2><ul><li>Alpha activity disappears normally with attention (eg, mental arithmetic, opening eyes). In most instances, it is regarded as a normal waveform.</li><li>An abnormal exception is alpha coma, most often caused by hypoxic-ischemic encephalopathy of destructive processes in the pons (eg, intracerebral hemorrhage). In alpha coma, alpha waves are distributed uniformly both anteriorly and posteriorly in patients who are unresponsive to stimuli.</li></ul><h2 id=\"beta-waves\">Beta waves</h2><ul><li>They tend to be small in amplitude and usually are symmetric and more evident anteriorly.</li><li>Barbituates, benzodiazepines, bad brain</li></ul><h2 id=\"theta-waves\">Theta waves</h2><ul><li>Theta waves normally are seen in sleep at any age. In awake adults, these waves are abnormal if they occur in excess.</li><li>Theta and delta waves are known collectively as slow waves.</li></ul><h2 id=\"delta-waves\">Delta waves</h2><ul><li>These slow waves have a frequency of 3 Hz or less.</li><li>They normally are seen in deep sleep in adults as well as in infants and children.</li><li>Delta waves are abnormal in the awake adult.</li><li>Often, they have the largest amplitude of all waves.</li><li>Delta waves can be focal (local pathology) or diffuse (generalized dysfunction).</li></ul>\n<h1 id=\"valproic-acid-toxicity\">Valproic Acid (VPA) Toxicity</h1>\n\n<h2 id=\"vpa-hyperammonemic-encephalopathy\">VPA-Induced Hyperammonemic Encephalopathy</h2>\n<p>Can occur even with therapeutic VPA levels. Suspect in any patient on VPA with acute confusion, lethargy, vomiting, or worsening seizures.</p>\n\n<h3 id=\"vpa-toxicity-recognition\">Recognition</h3>\n<div class=\"red-flag-box\">\n<p><strong>Check ammonia level in any encephalopathic patient on valproic acid — even if VPA level is \"therapeutic.\"</strong></p>\n<ul>\n<li>Ammonia &gt; 80 µmol/L — clinically significant</li>\n<li>Ammonia &gt; 100 µmol/L — concerning, likely symptomatic</li>\n<li>Ammonia &gt; 200 µmol/L — critical, risk of cerebral edema</li>\n</ul>\n<p>Also check: hepatic function panel (AST, ALT, total/direct bilirubin), VPA level, CBC with platelets, lipase</p>\n</div>\n\n<h3 id=\"l-carnitine-protocol\">L-Carnitine Treatment Protocol</h3>\n<div class=\"protocol-box\">\n<p><strong>Indication:</strong> VPA-induced hyperammonemia with encephalopathy, VPA overdose, or hepatotoxicity.</p>\n<p><strong>IV Levocarnitine (Carnitor):</strong></p>\n<ul>\n<li><strong>Loading dose:</strong> 100 mg/kg IV (max 6 g) over 30 minutes</li>\n<li><strong>Maintenance:</strong> 50 mg/kg IV (max 3 g) every 8 hours</li>\n<li>Continue until ammonia normalizes and mental status improves</li>\n<li>Transition to oral: 50-100 mg/kg/day divided TID (max 3 g/day)</li>\n</ul>\n<p><strong>Additional management:</strong></p>\n<ul>\n<li>Hold VPA immediately</li>\n<li>Consider lactulose if ammonia critically elevated (&gt; 200 µmol/L)</li>\n<li>Monitor ammonia every 4-6 hours until trending down</li>\n<li>If on VPA + other enzyme inducers (phenytoin, carbamazepine, phenobarbital) → higher risk of carnitine depletion</li>\n</ul>\n</div>\n\n<h3 id=\"vpa-overdose-management\">VPA Overdose</h3>\n<ul>\n<li><strong>VPA level &gt; 150 mg/L:</strong> Significant toxicity likely — L-carnitine, supportive care</li>\n<li><strong>VPA level &gt; 300 mg/L:</strong> Severe — consider hemodialysis (VPA is protein-bound at therapeutic levels but saturation occurs at high concentrations, making dialysis more effective)</li>\n<li><strong>VPA level &gt; 850 mg/L:</strong> Life-threatening — hemodialysis strongly recommended</li>\n<li>Activated charcoal if within 1-2 hours of ingestion (VPA is well-absorbed)</li>\n<li>No specific antidote — L-carnitine is the primary treatment adjunct</li>\n</ul>",
  "imageCount": 51,
  "chunkCount": 39
}